OMEGA HEALTHCARE INVESTORS INC 10-Q

Item 1 - Financial Statements OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except per share amounts) ​ ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ 2023 2022 ​ ​ (Unaudited) ​ ​ ​ ASSETS ​ ​ ​ ​ ​ Real estate assets ​ ​ Buildings and improvements ​ $ 7,398,122 $ 7,347,853 Land ​ ​ 928,318 ​ ​ 923,605 Furniture and equipment ​ ​ 499,102 ​ ​ 499,902 Construction in progress ​ ​ 107,983 ​ ​ 88,904 Total real estate assets ​ ​ 8,933,525 ​ ​ 8,860,264 Less accumulated depreciation ​ ( 2,444,149 ) ( 2,322,773 ) Real estate assets – net ​ 6,489,376 6,537,491 Investments in direct financing leases – net ​ 8,995 8,503 Real estate loans receivable – net ​ 1,096,806 1,042,731 Investments in unconsolidated joint ventures ​ 191,667 178,920 Assets held for sale ​ 1,400 9,456 Total real estate investments ​ ​ 7,788,244 ​ ​ 7,777,101 Non-real estate loans receivable – net ​ 227,916 225,281 Total investments ​ 8,016,160 8,002,382 ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ 350,691 297,103 Restricted cash ​ 5,820 3,541 Contractual receivables – net ​ 8,837 8,228 Other receivables and lease inducements ​ ​ 200,650 ​ ​ 177,798 Goodwill ​ 643,862 643,151 Other assets ​ 178,013 272,960 Total assets ​ $ 9,404,033 $ 9,405,163 ​ ​ ​ ​ ​ ​ ​ LIABILITIES AND EQUITY ​ Revolving credit facility ​ $ 20,342 $ 19,246 Secured borrowings ​ 360,775 366,596 Senior notes and other unsecured borrowings – net ​ 4,905,761 4,900,992 Accrued expenses and other liabilities ​ 304,563 315,047 Total liabilities ​ 5,591,441 5,601,881 ​ ​ ​ ​ ​ ​ ​ Equity: ​ ​ Preferred stock $ 1.00 par value authorized – 20,000 shares, issued and outstanding – none ​ ​ — ​ ​ — Common stock $ 0.10 par value authorized – 350,000 shares, issued and outstanding – 240,991 shares as of June 30, 2023 and 234,252 shares as of December 31, 2022 ​ 24,099 ​ 23,425 Additional paid-in capital ​ 6,526,367 ​ 6,314,203 Cumulative net earnings ​ 3,534,199 ​ 3,438,401 Cumulative dividends paid ​ ( 6,501,899 ) ​ ( 6,186,986 ) Accumulated other comprehensive income ​ 41,353 ​ 20,325 Total stockholders’ equity ​ 3,624,119 ​ 3,609,368 Noncontrolling interest ​ 188,473 ​ 193,914 Total equity ​ 3,812,592 ​ 3,803,282 Total liabilities and equity ​ $ 9,404,033 $ 9,405,163 See notes to consolidated financial statements . 2 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS Unaudited (in thousands, except per share amounts) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ June 30, June 30, ​ 2023 2022 2023 2022 Revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rental income ​ $ 219,101 ​ $ 211,428 $ 408,178 ​ $ 428,311 Income from direct financing leases ​ 254 ​ 256 508 ​ 512 Interest income ​ 29,232 ​ 31,374 57,652 ​ 62,517 Miscellaneous income ​ 1,600 ​ 1,591 2,051 ​ 2,624 Total revenues ​ 250,187 ​ 244,649 468,389 ​ 493,964 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Expenses ​ ​ ​ Depreciation and amortization ​ 82,018 ​ 83,207 163,210 ​ 165,959 General and administrative ​ 22,158 ​ 18,775 42,684 ​ 35,160 Real estate taxes ​ ​ 3,925 ​ ​ 3,717 ​ ​ 7,922 ​ ​ 7,320 Acquisition, merger and transition related costs ​ 423 ​ 3,960 1,062 ​ 5,473 Impairment on real estate properties ​ 21,114 ​ 7,695 60,102 ​ 11,206 Provision (recovery) for credit losses ​ 12,967 ​ ( 1,563 ) 8,910 ​ 261 Interest expense ​ 58,776 ​ 58,372 117,322 ​ 116,517 Total expenses ​ 201,381 ​ 174,163 401,212 ​ 341,896 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other income (expense) ​ ​ ​ ​ ​ Other income (expense) – net ​ 1,029 ​ ( 4,407 ) 3,749 ​ ( 4,862 ) Loss on debt extinguishment ​ — ​ ( 7 ) ( 6 ) ​ ( 13 ) Gain on assets sold – net ​ ​ 12,243 ​ ​ 25,180 ​ ​ 25,880 ​ ​ 138,817 Total other income ​ 13,272 ​ 20,766 29,623 ​ 133,942 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income before income tax expense and income from unconsolidated joint ventures ​ 62,078 ​ 91,252 96,800 ​ 286,010 Income tax expense ​ ( 1,626 ) ​ ( 1,119 ) ( 334 ) ​ ( 2,344 ) Income from unconsolidated joint ventures ​ 1,069 ​ 1,782 1,900 ​ 3,405 Net income ​ 61,521 ​ 91,915 98,366 ​ 287,071 Net income attributable to noncontrolling interest ​ ( 1,665 ) ​ ( 2,448 ) ( 2,568 ) ​ ( 7,997 ) Net income available to common stockholders ​ $ 59,856 ​ $ 89,467 $ 95,798 ​ $ 279,074 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings per common share available to common stockholders: ​ ​ ​ Basic: ​ ​ ​ ​ Net income available to common stockholders ​ $ 0.25 ​ $ 0.38 $ 0.41 ​ $ 1.17 Diluted: ​ ​ ​ Net income available to common stockholders ​ $ 0.25 ​ $ 0.38 $ 0.40 ​ $ 1.17 ​ See notes to consolidated financial statements . ​ 3 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Unaudited (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2023 2022 2023 2022 Net income $ 61,521 ​ $ 91,915 ​ $ 98,366 ​ $ 287,071 Other comprehensive income (loss) ​ ​ ​ ​ ​ Foreign currency translation 13,207 ​ ( 22,341 ) ​ 24,000 ​ ( 33,150 ) Cash flow hedges 7,199 ​ 19,444 ​ ( 2,351 ) ​ 39,022 Total other comprehensive income (loss) 20,406 ​ ( 2,897 ) ​ 21,649 ​ 5,872 Comprehensive income 81,927 ​ 89,018 ​ 120,015 ​ 292,943 Comprehensive income attributable to noncontrolling interest ( 2,251 ) ​ ( 2,368 ) ​ ( 3,189 ) ​ ( 8,168 ) Comprehensive income attributable to common stockholders $ 79,676 ​ $ 86,650 ​ $ 116,826 ​ $ 284,775 ​ See notes to consolidated financial statements. ​ ​ 4 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF EQUITY Three Months Ended June 30, 2023 and 2022 Unaudited (in thousands, except per share amounts) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common ​ Additional ​ Cumulative ​ Cumulative ​ Other ​ Total ​ ​ ​ ​ ​ ​ Stock ​ Paid-in ​ Net ​ Dividends ​ Comprehensive ​ Stockholders’ ​ Noncontrolling ​ Total ​ Par Value Capital Earnings Paid Income Equity Interest Equity Balance at March 31, 2023 ​ $ 23,434 ​ $ 6,322,160 ​ $ 3,474,343 ​ $ ( 6,344,413 ) ​ $ 21,533 ​ $ 3,497,057 ​ $ 188,554 ​ $ 3,685,611 Stock related compensation ​ ​ — ​ ​ 8,855 ​ ​ — ​ ​ — ​ ​ — ​ ​ 8,855 ​ ​ — ​ ​ 8,855 Issuance of common stock ​ ​ 663 ​ ​ 198,963 ​ ​ — ​ ​ — ​ ​ — ​ ​ 199,626 ​ ​ — ​ ​ 199,626 Common dividends declared ($ 0.67 per share) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 157,486 ) ​ ​ — ​ ​ ( 157,486 ) ​ ​ — ​ ​ ( 157,486 ) Vesting/exercising of Omega OP Units ​ ​ — ​ ​ ( 4,118 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 4,118 ) ​ ​ 4,118 ​ ​ — Conversion and redemption of Omega OP Units to common stock ​ ​ 2 ​ ​ 542 ​ ​ — ​ ​ — ​ ​ — ​ ​ 544 ​ ​ ( 621 ) ​ ​ ( 77 ) Omega OP Units distributions ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 5,636 ) ​ ​ ( 5,636 ) Net change in noncontrolling interest holder in consolidated JV ​ ​ — ​ ​ ( 35 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 35 ) ​ ​ ( 193 ) ​ ​ ( 228 ) Other comprehensive income ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 19,820 ​ ​ 19,820 ​ ​ 586 ​ ​ 20,406 Net income ​ ​ — ​ ​ — ​ ​ 59,856 ​ ​ — ​ ​ — ​ ​ 59,856 ​ ​ 1,665 ​ ​ 61,521 Balance at June 30, 2023 ​ $ 24,099 ​ $ 6,526,367 ​ $ 3,534,199 ​ $ ( 6,501,899 ) ​ $ 41,353 ​ $ 3,624,119 ​ $ 188,473 ​ $ 3,812,592 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at March 31, 2022 ​ $ 23,820 ​ $ 6,401,207 ​ $ 3,201,081 ​ $ ( 5,714,595 ) ​ $ 6,318 ​ $ 3,917,831 ​ $ 212,013 ​ $ 4,129,844 Stock related compensation ​ ​ — ​ ​ 6,892 ​ ​ — ​ ​ — ​ ​ — ​ ​ 6,892 ​ ​ — ​ ​ 6,892 Issuance of common stock ​ ​ 13 ​ ​ 2,331 ​ ​ — ​ ​ — ​ ​ — ​ ​ 2,344 ​ ​ — ​ ​ 2,344 Repurchase of common stock ​ ​ ( 423 ) ​ ​ ( 114,523 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 114,946 ) ​ ​ — ​ ​ ( 114,946 ) Common dividends declared ($ 0.67 per share) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 157,674 ) ​ ​ — ​ ​ ( 157,674 ) ​ ​ — ​ ​ ( 157,674 ) Conversion and redemption of Omega OP Units to common stock ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 9,704 ) ​ ​ ( 9,704 ) Omega OP Units distributions ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 5,062 ) ​ ​ ( 5,062 ) Other comprehensive loss ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 2,817 ) ​ ​ ( 2,817 ) ​ ​ ( 80 ) ​ ​ ( 2,897 ) Net income ​ ​ — ​ ​ — ​ ​ 89,467 ​ ​ — ​ ​ — ​ ​ 89,467 ​ ​ 2,448 ​ ​ 91,915 Balance at June 30, 2022 ​ $ 23,410 ​ $ 6,295,907 ​ $ 3,290,548 ​ $ ( 5,872,269 ) ​ $ 3,501 ​ $ 3,741,097 ​ $ 199,615 ​ $ 3,940,712 ​ See notes to consolidated financial statements. ​ ​ 5 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF EQUITY Six Months Ended June 30, 2023 and 2022 Unaudited (in thousands, except per share amounts) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common ​ Additional ​ Cumulative ​ Cumulative ​ Other ​ Total ​ ​ ​ ​ ​ ​ Stock ​ Paid-in ​ Net ​ Dividends ​ Comprehensive ​ Stockholders’ ​ Noncontrolling ​ Total ​ Par Value Capital Earnings Paid Income (Loss) Equity Interest Equity Balance at December 31, 2022 ​ $ 23,425 ​ $ 6,314,203 ​ $ 3,438,401 ​ $ ( 6,186,986 ) ​ $ 20,325 ​ $ 3,609,368 ​ $ 193,914 ​ $ 3,803,282 Stock related compensation ​ ​ — ​ ​ 17,647 ​ ​ — ​ ​ — ​ ​ — ​ ​ 17,647 ​ ​ — ​ ​ 17,647 Issuance of common stock ​ ​ 672 ​ ​ 200,939 ​ ​ — ​ ​ — ​ ​ — ​ ​ 201,611 ​ ​ — ​ ​ 201,611 Common dividends declared ($ 1.34 per share) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 314,913 ) ​ ​ — ​ ​ ( 314,913 ) ​ ​ — ​ ​ ( 314,913 ) Vesting/exercising of Omega OP Units ​ ​ — ​ ​ ( 6,929 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 6,929 ) ​ ​ 6,929 ​ ​ — Conversion and redemption of Omega OP Units to common stock ​ ​ 2 ​ ​ 542 ​ ​ — ​ ​ — ​ ​ — ​ ​ 544 ​ ​ ( 621 ) ​ ​ ( 77 ) Omega OP Units distributions ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 14,767 ) ​ ​ ( 14,767 ) Net change in noncontrolling interest holder in consolidated JV ​ ​ — ​ ​ ( 35 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 35 ) ​ ​ ( 171 ) ​ ​ ( 206 ) Other comprehensive income ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 21,028 ​ ​ 21,028 ​ ​ 621 ​ ​ 21,649 Net income ​ ​ — ​ ​ — ​ ​ 95,798 ​ ​ — ​ ​ — ​ ​ 95,798 ​ ​ 2,568 ​ ​ 98,366 Balance at June 30, 2023 ​ $ 24,099 ​ $ 6,526,367 ​ $ 3,534,199 ​ $ ( 6,501,899 ) ​ $ 41,353 ​ $ 3,624,119 ​ $ 188,473 ​ $ 3,812,592 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2021 ​ $ 23,906 ​ $ 6,427,566 ​ $ 3,011,474 ​ $ ( 5,553,908 ) ​ $ ( 2,200 ) ​ $ 3,906,838 ​ $ 201,388 ​ $ 4,108,226 Stock related compensation ​ ​ — ​ ​ 13,797 ​ ​ — ​ ​ — ​ ​ — ​ ​ 13,797 ​ ​ — ​ ​ 13,797 Issuance of common stock ​ ​ 25 ​ ​ 3,466 ​ ​ — ​ ​ — ​ ​ — ​ ​ 3,491 ​ ​ — ​ ​ 3,491 Repurchase of common stock ​ ​ ( 521 ) ​ ​ ( 141,746 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 142,267 ) ​ ​ — ​ ​ ( 142,267 ) Common dividends declared ($ 1.34 per share) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 318,361 ) ​ ​ — ​ ​ ( 318,361 ) ​ ​ — ​ ​ ( 318,361 ) Vesting/exercising of Omega OP Units ​ ​ — ​ ​ ( 7,176 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 7,176 ) ​ ​ 7,176 ​ ​ — Conversion and redemption of Omega OP Units to common stock ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 9,704 ) ​ ​ ( 9,704 ) Omega OP Units distributions ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 10,338 ) ​ ​ ( 10,338 ) Capital contribution from noncontrolling interest holder in consolidated JV ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 2,925 ​ ​ 2,925 Other comprehensive income ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 5,701 ​ ​ 5,701 ​ ​ 171 ​ ​ 5,872 Net income ​ ​ — ​ ​ — ​ ​ 279,074 ​ ​ — ​ ​ — ​ ​ 279,074 ​ ​ 7,997 ​ ​ 287,071 Balance at June 30, 2022 ​ $ 23,410 ​ $ 6,295,907 ​ $ 3,290,548 ​ $ ( 5,872,269 ) ​ $ 3,501 ​ $ 3,741,097 ​ $ 199,615 ​ $ 3,940,712 ​ See notes to consolidated financial statements. ​ ​ ​ ​ ​ ​ ​ ​ ​ 6 Table of Contents ​ OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2023 2022 Cash flows from operating activities ​ ​ Net income ​ $ 98,366 ​ $ 287,071 Adjustment to reconcile net income to net cash provided by operating activities: ​ ​ ​ Depreciation and amortization ​ 163,210 ​ 165,959 Impairment on real estate properties ​ 60,102 ​ 11,206 Provision for rental income ​ 13,401 ​ 14,805 Provision for credit losses ​ 8,910 ​ 261 Amortization of deferred financing costs and loss on debt extinguishment ​ 6,510 ​ 6,457 Accretion of direct financing leases ​ 53 ​ 38 Stock-based compensation expense ​ 17,550 ​ 13,706 Gain on assets sold – net ​ ( 25,880 ) ​ ( 138,817 ) Amortization of acquired in-place leases – net ​ ( 6,775 ) ​ ( 2,584 ) Straight-line rent and effective interest receivables ​ ( 23,257 ) ​ ( 39,082 ) Interest paid-in-kind ​ ​ ( 5,221 ) ​ ​ ( 4,511 ) Loss (income) from unconsolidated joint ventures ​ ​ 37 ​ ​ ( 1,503 ) Change in operating assets and liabilities – net: ​ ​ ​ Contractual receivables ​ ( 610 ) ​ 902 Lease inducements ​ ( 12,146 ) ​ 3,865 Other operating assets and liabilities ​ ( 12,514 ) ​ ( 12,577 ) Net cash provided by operating activities ​ 281,736 ​ 305,196 Cash flows from investing activities ​ ​ ​ ​ Acquisition of real estate ​ ( 154,927 ) ​ ( 113,168 ) Net proceeds from sale of real estate investments ​ 62,284 ​ 386,861 Investments in construction in progress ​ ( 14,681 ) ​ ( 7,978 ) Placement of loan principal ​ ( 182,728 ) ​ ( 203,720 ) Collection of loan principal ​ 121,918 ​ 239,803 Investments in unconsolidated joint ventures ​ ​ ( 8,195 ) ​ ​ ( 113 ) Distributions from unconsolidated joint ventures in excess of earnings ​ 1,134 ​ 1,176 Capital improvements to real estate investments ​ ( 13,191 ) ​ ( 26,260 ) Receipts from insurance proceeds ​ 3,717 ​ 565 Net cash (used in) provided by investing activities ​ ( 184,669 ) ​ 277,166 Cash flows from financing activities ​ ​ Proceeds from long-term borrowings ​ 80,000 ​ 515,208 Payments of long-term borrowings ​ ( 86,001 ) ​ ( 474,886 ) Payments of financing related costs ​ ( 6 ) ​ ( 13 ) Net proceeds from issuance of common stock ​ 201,611 ​ 3,491 Repurchase of common stock ​ ​ — ​ ​ ( 142,267 ) Dividends paid ​ ( 314,816 ) ​ ( 318,269 ) Net payments to noncontrolling members of consolidated joint venture ​ ( 206 ) ​ 22 Proceeds from derivative instruments ​ ​ 92,577 ​ ​ — Redemption of Omega OP Units ​ ​ ( 77 ) ​ ​ ( 9,704 ) Distributions to Omega OP Unit Holders ​ ( 14,767 ) ​ ( 10,338 ) Net cash used in financing activities ​ ( 41,685 ) ​ ( 436,756 ) Effect of foreign currency translation on cash, cash equivalents and restricted cash ​ 485 ​ ( 1,553 ) Increase in cash, cash equivalents and restricted cash ​ 55,867 ​ 144,053 Cash, cash equivalents and restricted cash at beginning of period ​ 300,644 ​ 24,411 Cash, cash equivalents and restricted cash at end of period ​ $ 356,511 ​ $ 168,464 ​ See notes to consolidated financial statements . ​ ​ 7 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Unaudited June 30, 2023 ​ NOTE 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Business Overview and Organization Omega Healthcare Investors, Inc. (“Parent”) is a Maryland corporation that, together with its consolidated subsidiaries (collectively, “Omega,” the “Company,” “we,” “our,” or “us”) invests in healthcare-related real estate properties located in the United States (“U.S.”) and the United Kingdom (“U.K.”). Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (“SNFs”), assisted living facilities (“ALFs”), and to a lesser extent, independent living facilities (“ILFs”), rehabilitation and acute care facilities (“specialty facilities”) and medical office buildings. Our core portfolio consists of long-term “triple net” leases and real estate loans with healthcare operating companies and affiliates (collectively, our “operators”). In addition to our core investments, we make loans to operators and/or their principals. From time to time, we also acquire equity interests in joint ventures or entities that support the long-term healthcare industry and our operators. Omega has elected to be taxed as a real estate investment trust (“REIT”) for federal income tax purposes and is structured as an umbrella partnership REIT (“UPREIT”) under which all of Omega’s assets are owned directly or indirectly by, and all of Omega’s operations are conducted directly or indirectly through, its operating partnership subsidiary, OHI Healthcare Properties Limited Partnership (collectively with its subsidiaries, “Omega OP”). Omega has exclusive control over Omega OP’s day-to-day management pursuant to the partnership agreement governing Omega OP. As of June 30, 2023, Parent owned approximately 97 % of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and other investors owned approximately 3 % of the outstanding Omega OP Units. Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022. Omega’s consolidated financial statements include the accounts of (i) Parent, (ii) all direct and indirect wholly owned subsidiaries of Omega, including Omega OP, (iii) other entities in which Omega or Omega OP has a majority voting interest and control and (iv) variable interest entities (“VIEs”) of which Omega is the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation, and Omega’s net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. Segments We conduct our operations and report financial results as one business segment. The presentation of financial results as one reportable segment is consistent with the way we operate our business and is consistent with the manner in which our Chief Operating Decision Maker (CODM), our Chief Executive Officer, evaluates performance and makes resource and operating decisions for the business. 8 Table of Contents Reclassification Certain line items on our Consolidated Statements of Operations and Consolidated Statements of Cash Flows have been reclassified to conform to the current period presentation. Risks and Uncertainties including COVID-19 The Company is subject to certain risks and uncertainties affecting the healthcare industry, including those that arose from the novel coronavirus (“COVID-19”) global pandemic, which disproportionately impacted the senior care sector, as well as those stemming from healthcare legislation and changing regulation by federal, state and local governments. Additionally, we are subject to risks and uncertainties as a result of changes affecting operators of nursing home facilities due to the actions of governmental agencies and insurers to limit the rising cost of healthcare services. Recent Accounting Pronouncements ASU – 2020-04, Financial Instruments – Reference Rate Reform (Topic 848) On March 12, 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, which contains optional practical expedients for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). The guidance may be elected over time until December 31, 2022, as reference rate reform activities occur. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which extended the practical expedients under ASU 2020-04 to December 31, 2024. The Company had several derivative instruments that referenced LIBOR which were terminated during the second quarter of 2023 (see Note 16 – Derivatives and Hedging). The Company also had a $ 1.45 billion senior unsecured multicurrency revolving credit facility and a $ 50.0 million senior unsecured term loan facility (see Note 15 – Borrowing Activities and Arrangements) that referenced LIBOR. During the second quarter of 2023, the Company amended its $ 1.45 billion senior unsecured multicurrency revolving credit facility and $ 50.0 million senior unsecured term loan facility to adjust the interest on each loan from a LIBOR based interest rate to a Secured Overnight Financing Rate (“SOFR”) based interest rate. For both loans we have elected to apply the optional expedient pursuant to Topic 848. As such we will account for the amendments as if the modifications were not substantial and thus a continuation of the existing contract resulting in no change to the current loan carrying values or the related deferred financing costs. NOTE 2 – REAL ESTATE ASSETS At June 30, 2023, our leased real estate properties included 660 SNFs, 175 ALFs, 19 ILFs, 17 specialty facilities and one medical office building. The following table summarizes the Company’s rental income from operating leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ ​ Six Months Ended June 30, ​ ​ 2023 ​ 2022 ​ ​ 2023 ​ 2022 ​ ​ (in thousands) ​ ​ (in thousands) Rental income – operating leases ​ $ 215,307 ​ $ 207,791 ​ ​ $ 400,634 ​ $ 421,388 Variable lease income – operating leases ​ ​ 3,794 ​ ​ 3,637 ​ ​ ​ 7,544 ​ ​ 6,923 Total rental income ​ $ 219,101 ​ $ 211,428 ​ ​ $ 408,178 ​ $ 428,311 ​ Our variable lease income primarily represents the reimbursement of real estate taxes and ground lease expenses by operators that Omega pays directly. 9 Table of Contents Asset Acquisitions The following table summarizes the asset acquisitions that occurred during the six months ended June 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ ​ ​ Total Real Estate ​ Initial ​ ​ Facilities ​ Assets Acquired Annual ​ Period ​ SNF ALF ​ Country/State ​ (in millions) ​ Cash Yield (1) ​ Q1 — 6 U.K. ​ $ 26.4 (2) 8.0 % Q2 ​ 4 — ​ WV ​ ​ 114.8 (3) 9.5 % Q2 ​ 1 — ​ WV ​ ​ 13.7 ​ 10.0 % Total 5 6 ​ $ 154.9 ​ ​ (1) Initial annual cash yield reflects the initial annual contractual cash rent divided by the purchase price. (2) In connection with this acquisition, the Company recorded $ 9.9 million of right-of-use assets and lease liabilities associated with ground leases assumed in the acquisition. (3) In connection with this acquisition, the Company also provided $ 104.6 million of mezzanine financing discussed further in Note 5 – Real Estate Loans Receivable and Note 6 – Non-Real Estate Loans Receivable. Construction in Progress and Capital Expenditure Investments We invested $ 17.8 million and $ 27.9 million under our construction in progress and capital improvement programs during the three and six months ended June 30, 2023, respectively. We invested $ 16.0 million and $ 34.2 million under our construction in progress and capital improvement programs during the three and six months ended June 30, 2022, respectively. During the second quarter of 2023, we purchased land located in Virginia (not reflected in the table above) for approximately $ 0.8 million that we plan to develop into a SNF. Concurrent with the acquisition, we amended our lease with an existing operator to include the land in the lease. We are committed to a maximum funding of $ 15.2 million for the development of the land. NOTE 3 – ASSETS HELD FOR SALE, DISPOSITIONS AND IMPAIRMENTS Periodically we sell facilities to reduce our exposure to certain operators, geographies and non-strategic assets or due to the exercise of a tenant purchase option. The following is a summary of our assets held for sale: ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2023 2022 Number of facilities held for sale ​ 1 ​ ​ 2 Amount of assets held for sale (in thousands) $ 1,400 ​ $ 9,456 ​ Asset Sales During the three and six months ended June 30, 2023, we sold ten facilities ( nine SNFs and one ILF) and 12 facilities ( ten SNFs, one ILF and one medical office building) subject to operating leases, for approximately $ 44.7 million and $ 62.3 million in net cash proceeds, respectively. As a result of these sales, we recognized net gains of approximately $ 12.2 million and $ 25.9 million, respectively. The proceeds for the three and six months ended June 30, 2023 primarily relate to the sale of five facilities in the second quarter of 2023 that were previously leased to Guardian Healthcare (“Guardian”) and were included in assets held for sale as of March 31, 2023. The net cash proceeds from the sale were $ 23.8 million, and we did no t recognize any gain or loss on the sale because we had already impaired the facilities down to the estimated fair value less costs to sell during the first quarter of 2023. Additionally, we sold one facility, also previously leased to Guardian, for a sales price of $ 12.0 million, which was fully financed by Omega through a $ 12.0 million first lien mortgage on the facility. The one facility sale and related seller financing did not meet the contract criteria to be recognized under ASC 610-20. During the three months ended June 30, 2023, we received interest of $ 0.2 million related to the seller financing, which was deferred and recorded as a contract liability within accrued expenses and other liabilities on our Consolidated Balance Sheets. 10 Table of Contents During the three and six months ended June 30, 2022, we sold 13 and 40 facilities, subject to operating leases, for approximately $ 54.3 million and $ 386.9 million in net cash proceeds, respectively. As a result of these sales, we recognized net gains of approximately $ 25.2 million and $ 138.8 million during the three and six months ended June 30, 2022, respectively. Our 2022 sales were primarily driven by restructuring transactions and negotiations related to our lease agreements with Gulf Coast Health Care LLC (together with certain affiliates “Gulf Coast”) and Guardian. In the first quarter of 2022, we sold 22 facilities that were previously leased and operated by Gulf Coast. The net cash proceeds from the sale, including previously accrued for related costs, were $ 304.0 million, and we recognized a net gain of $ 113.5 million. During the first and second quarter of 2022, we sold nine total facilities that were leased to Guardian for $ 39.5 million in net proceeds, which resulted in a net gain of $ 13.7 million. In December 2022, in connection with restructuring negotiations with LaVie Care Centers, LLC (“LaVie,” f/k/a Consulate Health Care), we sold 11 facilities previously leased to LaVie to a third party for a sales price of $ 129.8 million. Omega provided $ 104.8 million in senior seller financing, collateralized by first lien mortgages on the 11 facilities, to fund a portion of the purchase price. The 11-facility sale does not meet the contract criteria to be recognized under ASC 610-20. During the three and six months ended June 30, 2023, we received interest of $ 2.1 million and $ 4.2 million, respectively, related to the $ 104.8 million in senior seller financing, which was deferred and recorded as a contract liability within accrued expenses and other liabilities on our Consolidated Balance Sheets. Real Estate Impairments During the three and six months ended June 30, 2023, we recorded impairments on four and six facilities of approximately $ 21.1 million and $ 60.1 million, respectively. Of the $ 60.1 million, $ 57.5 million related to four held-for-use facilities (of which $ 48.0 million relates to three facilities that were closed during the year) for which the carrying value exceeded the fair value and $ 2.6 million related to two facilities that were classified as held for sale for which the carrying value exceeded the estimated fair value less costs to sell. During the three and six months ended June 30, 2022, we recorded impairments on four and six facilities of approximately $ 7.7 million and $ 11.2 million, respectively. Of the $ 11.2 million, $ 3.5 million related to two facilities that were classified as held for sale for which the carrying values exceeded the estimated fair values less costs to sell, and $ 7.7 million related to four held-for-use facilities for which the carrying value exceeded the fair value. To estimate the fair value of the facilities for the impairments noted above, we utilized a market approach that considered binding sale agreements (a Level 1 input) or non-binding offers from unrelated third parties and/or broker quotes (a Level 3 input). NOTE 4 – CONTRACTUAL RECEIVABLES AND OTHER RECEIVABLES AND LEASE INDUCEMENTS Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line rent receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception, modification or renewal of the lease, and are amortized as a reduction of rental income over the non-cancellable lease term. 11 Table of Contents A summary of our net receivables and lease inducements by type is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2023 2022 ​ ​ (in thousands) ​ Contractual receivables – net ​ $ 8,837 ​ $ 8,228 ​ ​ ​ ​ ​ ​ ​ ​ ​ Effective yield interest receivables ​ $ 4,603 ​ $ 5,696 ​ Straight-line rent receivables ​ 190,360 ​ 166,061 ​ Lease inducements ​ 5,687 ​ 6,041 ​ Other receivables and lease inducements ​ $ 200,650 ​ $ 177,798 ​ ​ Cash Basis Operators and Straight-Line Receivable Write-Offs We review our collectibility assumptions related to our operator leases on an ongoing basis. During the three and six months ended June 30, 2023, we placed two new operators, which Omega has not previously had relationships with prior to the second quarter of 2023, on a cash basis of revenue recognition as collection of substantially all contractual lease payments due from them was not deemed probable. The new lease agreements with each of these operators were executed in the second quarter of 2023 as part of transitions of facilities from other operators, and we placed them on a cash basis concurrent with the respective lease commencement dates, so there were no straight-line rent write-offs associated with moving these operators to a cash basis. During the three and six months ended June 30, 2022, we placed two and four operators, respectively, on a cash basis of revenue recognition as collection of substantially all contractual lease payments due from such operators was not deemed probable. In connection with moving these operators to a cash basis, we recognized $ 10.4 million in total straight-line accounts receivable write-offs through rental income during the three and six months ended June 30, 2022. During the six months ended June 30, 2023, we transitioned the portfolios of four cash basis operators with an aggregate of 48 facilities, including 14 facilities related to the operator referred to as the “ 1.2 % Operator” in our Annual Report on Form 10-K for the year ended December 31, 2022 and 20 facilities related to the operator referred to as the “ 2.0 % Operator” in our Annual Report on Form 10-K for the year ended December 31, 2022, to new or amended leases with five operators. We are recognizing revenue on a straight-line basis for the leases associated with these five operators. The aggregate initial contractual rent related to the 48 facilities following the transition to other operators is $ 48.0 million per annum. In connection with the transition of the 14 facilities, Omega made or agreed to make termination payments of $ 15.5 million in aggregate that were recorded as initial direct costs related to the lease with the new operator of the 14 transitioned facilities in the first quarter of 2023. These termination payments are deferred and recognized within depreciation and amortization expense on a straight-line basis over the term of the master lease. During the six months ended June 30, 2023 and 2022, we also wrote-off $ 0.9 million and $ 3.2 million, respectively, of straight-line rent receivable balances through rental income as a result of transitioning facilities between existing operators. As of June 30, 2023, we had 18 operators on a cash basis for revenue recognition, which represent 25.8 % and 32.3 % of our total revenues (excluding the impact of write-offs) for the six months ended June 30, 2023 and 2022, respectively. Rent Deferrals and Application of Collateral During the six months ended June 30, 2023 and 2022, we allowed nine operators and seven operators, respectively, to defer $ 33.6 million and $ 24.0 million, respectively, of contractual rent and interest. The deferrals during the six months ended June 30, 2023 primarily related to the following operators: LaVie ($ 19.0 million), Healthcare Homes Limited (“Healthcare Homes”) ($ 8.2 million), Agemo Holdings, LLC (“Agemo”) ($ 1.9 million) and Maplewood Senior Living (along with affiliates, “Maplewood”) ($ 0.7 million). 12 Table of Contents Additionally, we allowed four operators and five operators to apply collateral, such as security deposits or letters of credit, to contractual rent and interest during the six months ended June 30, 2023 and 2022, respectively. The total collateral applied to contractual rent and interest was $ 5.5 million and $ 4.7 million for the six months ended June 30, 2023 and 2022, respectively. Operator Collectibility Updates Agemo In the first quarter of 2023, Omega and Agemo entered into a restructuring agreement, an amended and restated master lease and a new loan agreement for two replacement loans. As part of the restructuring agreement and related agreements, Omega agreed to, among other things: ● Forgive and release Agemo from previously written off past due rent and interest obligations related to certain periods prior to the 2018 Agemo restructuring and from August 2021 through January 2023, with contractual rent under the lease agreement and contractual interest under the loan agreements scheduled to resume on April 1, 2023; ● reduce monthly contractual base rent from $ 4.8 million to $ 1.9 million following the sales of 22 facilities, previously leased and operated by Agemo, that occurred in the third and fourth quarters of 2022; ● extend the initial Agemo lease term from December 31, 2030 , to December 31, 2036 with three consecutive tenant 10-year extension options; and ● refinance and restructure the $ 25.0 million secured working capital loan (the “Agemo WC Loan”), the $ 32.0 million term loan (the “Agemo Term Loan”) and the aggregate deferred rent balance of $ 25.2 million into two replacement loans to Agemo that mature on December 31, 2036 , with aggregate principal of $ 82.2 million and an annual interest rate of 5.63 % through October 2024, which increases to 5.71 % until maturity. Agemo resumed making contractual rent payments during the second quarter of 2023 in accordance with the restructuring terms discussed above. Agemo is on a cash basis of revenue recognition for lease purposes, and we recorded rental income of $ 5.8 million for the three and six months ended June 30, 2023 for the contractual rent payments that were received. Additionally, no interest income was recognized during the three and six months ended June 30, 2023 and 2022 on the two loans with Agemo because these loans are on non-accrual status and we are utilizing the cost recovery method, under which any payments, if received, are applied against the principal amount. See Note 6 – Non-Real Estate Loans Receivable for further discussion on the impact of the restructuring on the loans. LaVie In the first quarter of 2023, Omega continued the process of restructuring our portfolio with LaVie and entered into lease amendments that allow for a partial rent deferral for the first four months of 2023. In doing so, we agreed to allow LaVie to defer up to $ 19.1 million of contractual rent from January 2023 through April 2023 under our lease agreements. During the three and six months ended June 30, 2023, LaVie elected to defer $ 4.7 million and $ 19.0 million, respectively, of contractual rent. Since LaVie was placed on a cash basis of revenue recognition for lease purposes in the fourth quarter of 2022, the $ 16.9 million and $ 24.3 million of contractual rent payments that we received from LaVie to satisfy the remaining contractual obligations after utilizing the deferral were recorded as rental income during the three and six months ended June 30, 2023, respectively. During the second quarter of 2023, we transitioned two facilities, previously subject to the master lease with LaVie, to another operator. In July 2023, LaVie paid $ 2.5 million of contractual rent, a short pay of $ 4.7 million of the $ 7.2 million due under its lease agreement. Revenue from LaVie represents approximately 5.1 % and 11.3 % of our total revenues (excluding the impact of write-offs) for the six months ended June 30, 2023 and 2022, respectively. 13 Table of Contents Maplewood In the first quarter of 2023, we agreed to a formal restructuring agreement, master lease amendments and loan amendments with Maplewood. As part of the restructuring agreement and related agreements, Omega agreed to, among other things: ● Extend the maturity date of the master lease from December 2033 to December 2037 with two consecutive 5-year tenant extension options; ● fix contractual rent at $ 69.3 million per annum (December 2022 rent annualized) and defer the 2.5 % annual escalators under our lease agreement through December 31, 2025, with mandatory repayments to be made subject to certain metrics and due in full by the maturity date; ● fund $ 22.5 million of capital expenditures through December 31, 2025; ● extend the maturity date of the secured revolving credit facility from June 2030 to June 2035 with one borrower 2-year extension option; ● increase the capacity of the secured revolving credit facility from $ 250.5 million to $ 320.0 million, inclusive of payment-in-kind (“PIK”) interest applied to principal ; ● convert the 7 % per annum cash interest due on the secured revolving credit facility to all PIK interest in 2023, 1 % cash interest and 6 % PIK interest in 2024, 4 % cash interest and 3 % PIK interest in 2025 and through the maturity date; ● pay a one-time option termination fee of $ 12.5 million to Maplewood; and ● reduce Maplewood’s share of any future potential sales proceeds (in excess of our gross investment) by the unpaid deferred rent balance, the $ 22.5 million of capital expenditures and the $ 12.5 million option termination fee payment. Maplewood short-paid the contractual rent amount due under its lease agreement in each of June 2023 and July 2023 by $ 1.0 million each. During the third quarter of 2023, we applied $ 2.0 million of Maplewood’s security deposit toward the unpaid portion of June 2023 rent and July 2023 rent. Following the application of the security deposit, we have a $ 2.8 million security deposit remaining. We are taking actions to preserve our rights and are in discussions with Maplewood to address the deficiency. Maplewood is on a cash basis of revenue recognition for lease purposes, and we recorded rental income of $ 16.3 million and $ 33.6 million for the three and six months ended June 30, 2023, respectively, for the contractual rent payments that were received. The $ 12.5 million option termination fee payment made in the first quarter of 2023 was accounted for as a lease inducement and recorded as a reduction to rental income since Maplewood is on a cash basis of revenue recognition. Additionally, as discussed further in Note 5 – Real Estate Loans Receivable, we recorded interest income of $ 1.5 million on the secured revolving credit facility during the three months ended March 31, 2023 for the contractual interest payment received related to December 2022, as the loan was placed on non-accrual status for interest recognition during the fourth quarter of 2022. Revenue from Maplewood represents approximately 7.3 % and 9.0 % of our total revenues (excluding the impact of write-offs) for the six months ended June 30, 2023 and 2022, respectively. 14 Table of Contents Healthcare Homes In December 2022, we agreed to allow Healthcare Homes, a U.K.-based operator representing 3.1 % and 2.9 % of our total revenues (excluding the impact of write-offs) for the six months ended June 30, 2023 and 2022, respectively, the ability to defer up to £ 6.7 million of contractual rent from January 2023 through April 2023 with regular payments required to resume in May 2023. The deferred rent balance accrues interest monthly at a rate of 8 % per annum and must be fully repaid by December 31, 2024. During the three and six months ended June 30, 2023, Healthcare Homes elected to defer £ 1.7 million ($ 2.1 million in USD) and £ 6.7 million ($ 8.2 million in USD), respectively, of contractual rent in accordance with the December 2022 agreement. Healthcare Homes is on a straight-line basis of revenue recognition. In May 2023, Healthcare Homes resumed making full contractual rent payments. NOTE 5 – REAL ESTATE LOANS RECEIVABLE Real estate loans consist of mortgage notes and other real estate loans which are primarily collateralized by a first, second or third mortgage lien or a leasehold mortgage on, or an assignment of the partnership interest in the related properties. As of June 30, 2023, our real estate loans receivable consists of eight fixed rate mortgage notes on 49 long-term care facilities and 12 other real estate loans. The mortgage notes relate to facilities located in six states that are operated by seven independent healthcare operating companies. We monitor compliance with our real estate loans and, when necessary, have initiated collection, foreclosure and other proceedings with respect to certain outstanding real estate loans. The principal amounts outstanding of real estate loans receivable, net of allowances, were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2023 2022 ​ ​ (in thousands) ​ Mortgage notes due 2030 ; interest at 11.01 % (1) ​ $ 509,475 $ 506,321 ​ Mortgage note due 2031 ; interest at 11.27 % ​ ​ — ​ ​ 76,049 ​ Mortgage note due 2037 ; interest at 10.50 % (2) ​ ​ 72,420 ​ ​ 72,420 ​ Mortgage note due 2025 ; interest at 7.85 % ​ ​ 62,921 ​ ​ 63,811 ​ Other mortgage notes outstanding (3) ​ 25,622 ​ 12,922 ​ Mortgage notes receivable – gross ​ 670,438 ​ 731,523 ​ Allowance for credit losses on mortgage notes receivable ​ ​ ( 40,226 ) ​ ​ ( 83,393 ) ​ Mortgage notes receivable – net ​ ​ 630,212 ​ ​ 648,130 ​ Other real estate loan due 2035 ; interest at 7.00 % ​ ​ 263,520 ​ ​ 250,500 ​ Other real estate loans due 2024 ; interest at 13.19 % (1) ​ ​ 102,535 ​ ​ 98,440 ​ Other real estate loans due 2023 - 2029 ; interest at 11.75 % (1) ​ ​ 103,307 ​ ​ 43,628 ​ Other real estate loan outstanding (4) ​ ​ 20,000 ​ ​ 20,000 ​ Other real estate loans – gross ​ ​ 489,362 ​ ​ 412,568 ​ Allowance for credit losses on other real estate loans ​ ( 22,768 ) ​ ( 17,967 ) ​ Other real estate loans – net ​ ​ 466,594 ​ ​ 394,601 ​ Total real estate loans receivable – net ​ $ 1,096,806 ​ $ 1,042,731 ​ (1) Approximates the weighted average interest rate on facilities as of June 30, 2023. (2) During the second quarter of 2023, this mortgage note was extended from December 31, 2032 to December 31, 2037. (3) Other mortgage notes outstanding have a weighted average interest rate of 8.6 % as of June 30, 2023, with maturity dates ranging from 2023 through 2026 . Two of the mortgage notes with an aggregate principal balance of $ 12.9 million are past due and have been written down, through our allowance for credit losses, to the estimated fair value of the underlying collateral of $ 1.5 million. (4) As of June 30, 2023 and December 31, 2022, includes one other real estate loan that bears interest at a rate of 12 % and matures on December 2, 2027 . 15 Table of Contents Interest revenue on real estate loans is included within interest income on the Consolidated Statements of Operations and is summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2023 2022 ​ 2023 2022 ​ (in thousands) ​ (in thousands) Mortgage notes – interest income $ 16,998 $ 19,597 ​ $ 33,546 $ 40,146 Other real estate loans – interest income 6,981 ​ 9,042 ​ 13,830 ​ 17,421 Total real estate loans interest income $ 23,979 ​ $ 28,639 ​ $ 47,376 ​ $ 57,567 ​ Mortgage note due 2031 In the second quarter of 2022, we agreed to a formal restructuring agreement and amended the mortgage loan with Guardian, which among other adjustments, extended the loan’s maturity date and allowed for the deferral of certain contractual interest. The loan amendment was treated as a loan modification provided to a borrower experiencing financial difficulty. Following the execution of the restructuring agreement, Guardian resumed paying contractual rent and interest during the second quarter of 2022 and continued such payments throughout the remainder of 2022 and the first and second quarters of 2023, in accordance with the restructuring terms. The mortgage loan is on non-accrual status and is being accounted for under the cost recovery method, under which any payments, if received, are applied against the principal amount. During the three and six months ended June 30, 2023, we received $ 1.6 million and $ 3.9 million, respectively, of interest payments from Guardian that we applied against the outstanding principal of the loan and recognized a recovery for credit loss equal to the amount of payments applied against principal. In the second quarter of 2023, Guardian completed the sale of the four remaining facilities subject to the mortgage note with Omega. Guardian used $ 35.2 million of proceeds from the sale of the facilities to make a principal repayment to Omega, in the same amount, against the mortgage note. Following the repayment, Omega agreed to release the mortgage liens on these facilities and forgive the remaining $ 46.8 million of outstanding principal due under the mortgage note. We had previously established an allowance for credit loss to reserve this loan down to $ 35.2 million in anticipation of this settlement. Other real estate loan due 2035 As discussed in Note 4 – Contractual Receivables and Other Receivables and Lease Inducements, in the first quarter of 2023, Omega entered into a restructuring agreement and a loan amendment with Maplewood that modified Maplewood’s secured revolving credit facility. As part of the restructuring agreement and loan amendment, Omega agreed to extend the maturity date of the facility to June 2035, increase the capacity of the secured revolving credit facility from $ 250.5 million to $ 320.0 million, including PIK interest applied to the principal, and to convert the 7 % cash interest due on the secured revolving credit facility to all PIK interest in 2023, 1 % cash interest and 6 % PIK interest in 2024, 4 % cash interest and 3 % PIK interest in 2025 and through the maturity date. The maximum PIK interest allowable under credit facility, as amended, is $ 52.2 million. This amendment was treated as a loan modification provided to a borrower experiencing financial difficulty. During the three months ended March 31, 2023, we recorded interest income of $ 1.5 million on the secured revolving credit facility for the contractual interest payment received related to December 2022, as the loan was placed on non-accrual status for interest recognition during the fourth quarter of 2022. We did not record any interest income related to the PIK interest during the three and six months ended June 30, 2023. As of June 30, 2023, the amortized cost basis of this loan was $ 263.5 million, which represents 22.7 % of the total amortized cost basis of all real estate loan receivables. As of June 30, 2023, the remaining commitment under the secured revolving credit facility, including the unrecognized PIK interest, was $ 48.8 million. 16 Table of Contents Other real estate loans due 2023-2029 On April 14, 2023, we entered into two mezzanine loans, with principal balances of $ 68.0 million and $ 6.6 million, respectively, with an existing operator and its affiliates in connection with the operator’s acquisition of 13 SNFs in West Virginia. The $ 68.0 million loan matures on April 13, 2029 and bears interest at a variable rate that results in a blended interest rate of 12 % per annum across this loan and three other loans, including the $ 6.6 million mezzanine loan and both $ 15.0 million mezzanine loans discussed under Notes due 2023-2029 in Note 6 – Non-Real Estate Loans Receivable. The $ 68.0 million loan requires quarterly principal payments of $ 1.0 million commencing on July 1, 2023 and additional payments contingent on certain metrics. The $ 68.0 million loan is secured by a leasehold mortgage and a pledge of the operator’s equity interest in subsidiaries of the operator. The $ 6.6 million mezzanine loan matures on April 14, 2029 and bears interest at a rate of 8 % per annum. The $ 6.6 million mezzanine loan was made to a new real estate joint venture, RCA NH Holdings RE Co., LLC, that we formed in April 2023 with the acquiring operator (see Note 9 – Investments in Joint Ventures for additional information on this joint venture). NOTE 6 – NON-REAL ESTATE LOANS RECEIVABLE Our non-real estate loans consist of fixed and variable rate loans to operators and/or principals. These loans may be either unsecured or secured by the collateral of the borrower, which may include the working capital of the borrower. As of June 30, 2023, we had 39 loans with 22 different borrowers. A summary of our non-real estate loans is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2023 2022 ​ ​ ​ (in thousands) ​ Notes due 2023 - 2029 ; interest at 11.30 % (1) ​ $ 86,763 ​ $ 55,981 ​ Notes due 2036 ; interest at 5.63 % ​ ​ 80,207 ​ 55,791 ​ Notes due 2036 ; interest at 2.00 % ​ ​ 32,308 ​ ​ 32,539 ​ Note due 2024 ; interest at 7.50 % ​ ​ 50,999 ​ ​ 47,999 ​ Note due 2027 ; interest at 12.00 % (2) ​ ​ — ​ ​ 39,653 ​ Other notes outstanding (3) ​ 93,318 ​ 77,186 ​ Non-real estate loans receivable – gross ​ ​ 343,595 ​ ​ 309,149 ​ Allowance for credit losses on non-real estate loans receivable ​ ​ ( 115,679 ) ​ ​ ( 83,868 ) ​ Total non-real estate loans receivable – net ​ $ 227,916 ​ $ 225,281 ​ (1) Approximates the weighted average interest rate as of June 30, 2023. (2) During the first quarter of 2023, this loan was fully repaid. (3) Other notes outstanding have a weighted average interest rate of 7.39 % as of June 30, 2023, with maturity dates ranging from 2023 through 2030 (with $ 19.6 million maturing in 2023 ). We have one loan within other notes outstanding with principal of $ 4.1 million that matured in 2022 but remained outstanding as of June 30, 2023. We wrote the $ 4.1 million loan down to the fair value of its collateral of $ 1.0 million during the first quarter of 2023. For the three months ended June 30, 2023 and 2022, non-real estate loans generated interest income of $ 5.3 million and $ 2.8 million, respectively. For the six months ended June 30, 2023 and 2022, non-real estate loans generated interest income of $ 10.3 million and $ 5.0 million, respectively. Interest income on non-real estate loans is included within interest income on the Consolidated Statements of Operations. 17 Table of Contents Notes due 2036 ; interest at 5.63 % As discussed in Note 4 – Contractual Receivables and Other Receivables and Lease Inducements, in the first quarter of 2023, Omega entered into a restructuring agreement and a replacement loan agreement that modified the existing Agemo loans. Under the restructuring agreement, previously written off contractual unpaid interest related to the Agemo WC Loan and the Agemo Term Loan was forgiven. The outstanding principal of the Agemo Term Loan was refinanced into a new $ 32.0 million loan (“Agemo Replacement Loan A”). The outstanding principal of the Agemo WC Loan and the aggregate rent deferred and outstanding under the Agemo lease agreement was combined and refinanced into a new $ 50.2 million loan (“Agemo Replacement Loan B” and with Agemo Replacement Loan A, the “Agemo Replacement Loans”). The Agemo Replacement Loans bear interest at 5.63 % per annum through October 2024, which increases to 5.71 % per annum until maturity. The Agemo Replacement Loans mature on December 31, 2036 . Interest payments were scheduled to resume on April 1, 2023, contingent upon Agemo’s compliance with certain conditions of the restructuring agreement; however, Agemo had the option to defer the interest payment due on April 1, 2023. Beginning in January 2025, Agemo will be required to make principal payments on the Agemo Replacement Loans dependent on certain metrics. These amendments were treated as loan modifications provided to a borrower experiencing financial difficulty. Both of these loans are on non-accrual status, and we are utilizing the cost recovery method, under which any payments, if received, are applied against the principal amount. Prior to the restructuring, the principal of the Agemo WC Loan and the Agemo Term Loan were written down to $ 5.9 million and zero , respectively, the fair value of the underlying collateral of these loans. No changes to the collateral supporting the loans were made because of the refinancing of these loans into the Agemo Replacement Loans. Additional principal of $ 25.2 million related to deferred rent due under the master lease was combined with the principal of the Agemo WC Loan under Agemo Replacement Loan B. This deferred rent balance was previously written off when the Agemo master lease was taken to a cash basis of revenue recognition in 2020. We believe it is not probable that we will collect the additional $ 25.2 million of principal balance associated with the deferred rent under Agemo Replacement Loan B. As such, we added an additional allowance for credit losses of $ 25.2 million related to Agemo Replacement Loan B concurrent with the increase in loan principal during the first quarter of 2023. There is no income statement impact as a result of this additional reserve due to the balance previously being written off. Agemo exercised its option to defer the interest payment due on April 1, 2023 and resumed making interest payments in May 2023 in accordance with the restructuring terms discussed above. During the three months ended June 30, 2023, we received $ 0.8 million of interest payments from Agemo that we applied against the outstanding principal of the loans and recognized a recovery for credit loss equal to the amount of payments applied against principal. As of June 30, 2023, the amortized cost basis of these loans was $ 80.2 million, which represents 23.3 % of the total amortized cost basis of all non-real estate loan receivables. The total reserve as of June 30, 2023 related to the Agemo Replacement Loans was $ 74.3 million. Notes due 2023 - 2029 During the second quarter of 2023, we entered into two $ 15.0 million mezzanine loans with an existing operator and its affiliates in connection with the operator’s acquisition of 13 SNFs in West Virginia (discussed in Note 5 – Real Estate Loans Receivable). The first $ 15.0 million mezzanine loan (the “2028 Mezz Loan”) matures on April 1, 2028 and bears interest at a variable rate based on the one month term SOFR plus 8.6 % per annum. The 2028 Mezz Loan requires monthly principal payments commencing on May 1, 2023 and is secured by a pledge of the operator’s equity interest in its subsidiaries. The second $ 15.0 million mezzanine loan (the “2029 Mezz Loan”) matures on April 13, 2029 and bears interest at a fixed rate of 12 % per annum. The 2029 Mezz Loan also requires quarterly principal payments of $ 0.3 million commencing on July 1, 2023 and additional payments contingent on the operator’s achievement of certain metrics. The 2029 Mezz Loan is secured by a pledge of the operator’s equity interest in subsidiaries of the operator. In connection with the two mezzanine loans, we also provided a $ 3.3 million working capital loan to a new joint venture, WV Pharm Holdings, LLC, that we formed in April 2023 with the acquiring operator (see Note 9 – Investments in Joint Ventures for additional information on this joint venture). 18 Table of Contents Notes due 2036 ; interest at 2.00 % During the fourth quarter of 2022, we amended an $ 8.3 million term loan and a $ 25.0 million term loan with LaVie to, among other terms, extend the loan maturities to November 30, 2036 to align with the lease term, and starting in January 2023, reduce the interest rates to 2 %, remove the requirement to make any principal payments until the maturity dates and convert from monthly cash interest payments to PIK interest. These amendments were treated as loan modifications provided to a borrower experiencing financial difficulty. Both of these loans are on non-accrual status, and we are utilizing the cost recovery method, under which any payments made by LaVie are applied against the principal amount outstanding. During the six months ended June 30, 2023, we applied an aggregate $ 0.2 million of interest payments received to the $ 25.0 million term loan principal balance and the $ 8.3 million term loan principal balance outstanding. As of June 30, 2023, the amortized cost basis of these loans was $ 32.3 million, which represents 9.4 % of the total amortized cost basis of all non-real estate loan receivables. The total reserve as of June 30, 2023 related to the LaVie loans was $ 24.8 million. Note due 2024 On July 8, 2019, the Company entered into a $ 15 million unsecured revolving credit facility agreement with a principal of an operator that bears interest at a fixed rate of 7.5 % per annum and originally matured on July 8, 2022 . During 2022, this revolving credit facility was amended multiple times to increase the maximum principal to $ 48 million, extend the maturity date to December 31, 2024 and require monthly principal payments. During the second quarter of 2023, this revolving credit facility was further amended to increase the maximum principal to $ 52 million and modify the principal payment schedule. Other notes outstanding $ 10.0 million Mezzanine Loan and Working Capital Loan On June 30, 2023, the Company entered into a $ 10.0 million mezzanine loan and a revolving working capital loan with an existing operator in connection with the operator’s acquisition of a portfolio of facilities in Pennsylvania. The $ 10.0 million mezzanine loan matures on June 30, 2028 and bears interest at a fixed rate of 11 % per annum. The $ 10.0 million mezzanine loan also requires monthly amortizing payments of principal and interest in the amount of $ 0.2 million. The $ 10.0 million mezzanine loan is secured by an equity interest in a subsidiary of the operator. The working capital loan matures on June 30, 2026 and bears interest at a fixed rate of 10 % per annum. The working capital loan has a maximum principal of $ 34.0 million for the first year that decreases to $ 20.0 million thereafter. The working capital loan is secured by the accounts receivable of the acquired facilities. As of June 30, 2023, the revolving working capital loan has not been drawn on. 19 Table of Contents NOTE 7 – ALLOWANCE FOR CREDIT LOSSES A rollforward of our allowance for credit losses for the six months ended June 30, 2023 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rating ​ Financial Statement Line Item Allowance for Credit Loss as of December 31, 2022 ​ Provision (recovery) for Credit Loss for the six months ended June 30, 2023 ​ Write-offs charged against allowance for the six months ended June 30, 2023 ​ Other additions to the allowance for the six months ended June 30, 2023 ​ Allowance for Credit Loss as of June 30, 2023 ​ ​ ​ (in thousands) 1 ​ Real estate loan receivable $ 162 ​ $ 366 ​ $ — ​ $ — ​ $ 528 2 ​ Real estate loans receivable ​ 157 ​ ​ ( 88 ) ​ ​ — ​ ​ — ​ ​ 69 3 ​ Real estate loans receivable ​ 15,110 ​ ​ ( 9,465 ) ​ ​ — ​ ​ — ​ ​ 5,645 4 ​ Real estate loans receivable ​ 33,666 ​ ​ 11,636 ​ ​ — ​ ​ — ​ ​ 45,302 6 ​ Real estate loans receivable ​ 52,265 ​ ​ ( 3,860 ) ​ ​ ( 36,955 ) (1) ​ — ​ ​ 11,450 ​ ​ Sub-total ​ 101,360 ​ ​ ( 1,411 ) ​ ​ ( 36,955 ) ​ ​ — ​ ​ 62,994 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 5 ​ Investment in direct financing leases ​ 2,816 ​ ​ ( 545 ) ​ ​ — ​ ​ — ​ ​ 2,271 ​ ​ Sub-total ​ 2,816 ​ ​ ( 545 ) ​ ​ — ​ ​ — ​ ​ 2,271 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 ​ Non-real estate loans receivable ​ 859 ​ ​ ( 507 ) ​ ​ — ​ ​ — ​ ​ 352 3 ​ Non-real estate loans receivable ​ 2,079 ​ ​ ( 1,016 ) ​ ​ — ​ ​ — ​ ​ 1,063 4 ​ Non-real estate loans receivable ​ 634 ​ ​ ( 430 ) ​ ​ — ​ ​ — ​ ​ 204 5 ​ Non-real estate loans receivable ​ 18,619 ​ ​ ( 439 ) ​ ​ — ​ ​ 25,200 (2) ​ 43,380 6 ​ Non-real estate loans receivable ​ 61,677 ​ ​ 9,003 ​ ​ — ​ ​ — ​ ​ 70,680 ​ ​ Sub-total ​ 83,868 ​ ​ 6,611 ​ ​ — ​ ​ 25,200 ​ ​ 115,679 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 ​ Off-balance sheet non-real estate loan commitments ​ 207 ​ ​ 177 ​ ​ — ​ ​ — ​ ​ 384 3 ​ Off-balance sheet non-real estate loan commitments ​ 29 ​ ​ ( 27 ) ​ ​ — ​ ​ — ​ ​ 2 4 ​ Off-balance sheet non-real estate loan commitments ​ — ​ ​ 8 ​ ​ — ​ ​ — ​ ​ 8 4 ​ Off-balance sheet real estate loan commitments ​ 84 ​ ​ 4,097 ​ ​ — ​ ​ — ​ ​ 4,181 ​ ​ Sub-total ​ 320 ​ ​ 4,255 ​ ​ — ​ ​ — ​ ​ 4,575 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ 188,364 ​ $ 8,910 ​ $ ( 36,955 ) ​ $ 25,200 ​ $ 185,519 (1) This amount relates to the write-off of the allowance for the Guardian mortgage note in connection with the settlement and partial forgiveness of the note in the second quarter of 2023. See Note 5 – Real Estate Loans Receivable for additional details. (2) This amount relates to the additional $ 25.2 million allowance recorded during the first quarter of 2023 in order to reserve the aggregate deferred rent amount that is included within Agemo Replacement Loan B. See Note 6 – Non-Real Estate Loans Receivable for additional details. 20 Table of Contents A rollforward of our allowance for credit losses for the six months ended June 30, 2022 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rating ​ Financial Statement Line Item Allowance for Credit Loss at December 31, 2021 ​ Provision (recovery) for Credit Loss for the six months ended June 30, 2022 ​ Write-offs charged against allowance for the six months ended June 30, 2022 ​ Allowance for Credit Loss as of June 30, 2022 ​ ​ ​ (in thousands) 1 ​ Real estate loans receivable $ — ​ $ 246 ​ $ — ​ $ 246 2 ​ Real estate loans receivable ​ 14 ​ ​ 13 ​ ​ — ​ ​ 27 3 ​ Real estate loans receivable ​ 5,367 ​ ​ 431 ​ ​ — ​ ​ 5,798 4 ​ Real estate loans receivable ​ 20,577 ​ ​ ( 2,814 ) ​ ​ — ​ ​ 17,763 5 ​ Real estate loans receivable ​ 136 ​ ​ ( 67 ) ​ ​ — ​ ​ 69 6 ​ Real estate loans receivable ​ 56,480 ​ ​ ( 6,584 ) (1) ​ — ​ ​ 49,896 ​ ​ Sub-total ​ 82,574 ​ ​ ( 8,775 ) ​ ​ — ​ ​ 73,799 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 3 ​ Investment in direct financing leases ​ 530 ​ ​ ( 47 ) ​ ​ — ​ ​ 483 ​ ​ Sub-total ​ 530 ​ ​ ( 47 ) ​ ​ — ​ ​ 483 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 ​ Non-real estate loans receivable ​ 29 ​ ​ 20 ​ ​ — ​ ​ 49 3 ​ Non-real estate loans receivable ​ 1,206 ​ ​ 1,820 (2) ​ — ​ ​ 3,026 4 ​ Non-real estate loans receivable ​ 56 ​ ​ 596 ​ ​ — ​ ​ 652 5 ​ Non-real estate loans receivable ​ 7,861 ​ ​ 5,993 (3) ​ — ​ ​ 13,854 6 ​ Non-real estate loans receivable ​ 51,269 ​ ​ ( 1,479 ) ​ ​ — ​ ​ 49,790 ​ ​ Sub-total ​ 60,421 ​ ​ 6,950 ​ ​ — ​ ​ 67,371 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 ​ Off-balance sheet non-real estate loan commitments ​ 7 ​ ​ 236 ​ ​ — ​ ​ 243 3 ​ Off-balance sheet non-real estate loan commitments ​ 207 ​ ​ 12 ​ ​ — ​ ​ 219 3 ​ Off-balance sheet real estate loan commitments ​ 251 ​ ​ 24 ​ ​ — ​ ​ 275 4 ​ Off-balance sheet non-real estate loan commitments ​ 216 ​ ​ ( 165 ) ​ ​ — ​ ​ 51 4 ​ Off-balance sheet real estate loan commitments ​ 117 ​ ​ ( 106 ) ​ ​ — ​ ​ 11 6 ​ Off-balance sheet non-real estate loan commitments ​ 143 ​ ​ 2,132 ​ ​ — ​ ​ 2,275 ​ ​ ​ ​ 941 ​ ​ 2,133 ​ ​ — ​ ​ 3,074 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ 144,466 ​ $ 261 ​ $ — ​ $ 144,727 (1) This amount relates to a recovery recorded on the Guardian mortgage loan during the first and second quarters of 2022. (2) This provision includes an additional $ 2.3 million allowance recorded on a $ 20 million working capital loan during the second quarter of 2022. (3) This provision includes an additional $ 4.7 million allowance recorded on the Agemo WC Loan during the first quarter of 2022 and an additional $ 1.3 million allowance recorded on the Agemo WC Loan during the second quarter of 2022. A summary of our amortized cost basis by year of origination and credit quality indicator is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rating Financial Statement Line Item 2023 2022 2021 2020 2019 2018 2017 & older Revolving Loans Balance as of June 30, 2023 ​ ​ (in thousands) 1 Real estate loans receivable $ — $ 20,000 $ — $ — $ — $ — $ 62,921 $ — $ 82,921 2 Real estate loans receivable ​ 7,700 ​ — ​ — ​ 21,325 ​ — ​ — ​ — ​ — ​ 29,025 3 Real estate loans receivable ​ 73,964 ​ 33,600 ​ 72,420 ​ — ​ — ​ — ​ 744 ​ — ​ 180,728 4 Real estate loans receivable ​ — ​ 210 ​ 31,820 ​ 89,463 ​ 5,099 ​ 131,632 ​ 332,460 ​ 263,520 ​ 854,204 6 Real estate loans receivable ​ — ​ — ​ — ​ — ​ — ​ — ​ 12,922 ​ — ​ 12,922 ​ Sub-total ​ 81,664 ​ 53,810 ​ 104,240 ​ 110,788 ​ 5,099 ​ 131,632 ​ 409,047 ​ 263,520 ​ 1,159,800 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 5 Investment in direct financing leases ​ — ​ — ​ — ​ — ​ — ​ — ​ 11,266 ​ — ​ 11,266 ​ Sub-total ​ — ​ — ​ — ​ — ​ — ​ — ​ 11,266 ​ — ​ 11,266 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 Non-real estate loans receivable ​ 1,300 ​ — ​ — ​ — ​ — ​ — ​ — ​ 100,249 ​ 101,549 3 Non-real estate loans receivable ​ 40,080 ​ 22,151 ​ — ​ — ​ 3,883 ​ 10,800 ​ — ​ 9,550 ​ 86,464 4 Non-real estate loans receivable ​ — ​ — ​ — ​ — ​ 1,630 ​ — ​ 1,000 ​ 21,400 ​ 24,030 5 Non-real estate loans receivable ​ — ​ — ​ — ​ — ​ 2,288 ​ 49,269 ​ — ​ — ​ 51,557 6 Non-real estate loans receivable ​ 7,936 ​ 24,457 ​ 7,851 ​ — ​ — ​ 4,092 ​ 30,938 ​ 4,721 ​ 79,995 ​ Sub-total ​ 49,316 ​ 46,608 ​ 7,851 ​ — ​ 7,801 ​ 64,161 ​ 31,938 ​ 135,920 ​ 343,595 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ 130,980 $ 100,418 $ 112,091 $ 110,788 $ 12,900 $ 195,793 $ 452,251 $ 399,440 $ 1,514,661 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year to date gross write-offs $ — $ — $ — $ — $ — $ — $ ( 36,955 ) $ — $ ( 36,955 ) ​ 21 Table of Contents Interest Receivable on Real Estate Loans and Non-Real Estate Loans We have elected the practical expedient to exclude interest receivable from our allowance for credit losses. As of June 30, 2023 and December 31, 2022, we have excluded $ 8.8 million and $ 8.2 million, respectively, of contractual interest receivables and $ 4.6 million and $ 5.7 million, respectively, of effective yield interest receivables from our allowance for credit losses. We write-off contractual interest receivables to provision for credit losses in the period we determine the interest is no longer considered collectible. During the three months ended June 30, 2023 and 2022, we recognized $ 0.1 million and $ 4.9 million, respectively, of interest income related to loans on non-accrual status as of June 30, 2023. During the six months ended June 30, 2023 and 2022, we recognized $ 1.6 million and $ 9.0 million, respectively, of interest income related to loans on non-accrual status as of June 30, 2023. NOTE 8 – VARIABLE INTEREST ENTITIES Unconsolidated Variable Interest Entities We hold variable interests in several VIEs through our investing and financing activities, which are not consolidated, as we have concluded that we are not the primary beneficiary of these entities as we do not have the power to direct activities that most significantly impact the VIE’s economic performance and/or the variable interest we hold does not obligate us to absorb losses or provide us with the right to receive benefits from the VIE which could potentially be significant. Below is a summary of our assets, liabilities, collateral and maximum exposure to loss associated with these unconsolidated VIEs as of June 30, 2023 and December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ ​ 2023 ​ 2022 ​ ​ ​ (in thousands) ​ Assets ​ ​ ​ ​ ​ ​ ​ Real estate assets – net ​ $ 1,047,319 ​ $ 982,721 ​ Real estate loans receivable – net ​ 302,816 ​ ​ 270,500 ​ Investments in unconsolidated joint ventures ​ ​ 8,150 ​ ​ — ​ Non-real estate loans receivable – net ​ 9,095 ​ ​ 5,929 ​ Contractual receivables – net ​ 194 ​ ​ 114 ​ Other assets ​ ​ 1,423 ​ ​ 1,499 ​ Total assets ​ 1,368,997 ​ 1,260,763 ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other liabilities ​ ​ ( 51,464 ) ​ ​ ( 50,522 ) ​ Total liabilities ​ ( 51,464 ) ​ ( 50,522 ) ​ ​ ​ ​ ​ ​ ​ ​ ​ Collateral ​ ​ ​ Personal guarantee ​ ( 48,000 ) ​ ​ ( 48,000 ) ​ Other collateral (1) ​ ( 1,060,019 ) ​ ​ ( 982,721 ) ​ Total collateral ​ ( 1,108,019 ) ​ ​ ( 1,030,721 ) ​ ​ ​ ​ ​ ​ ​ ​ ​ Maximum exposure to loss ​ $ 209,514 ​ $ 179,520 ​ (1) Amount excludes accounts receivable that Omega has a security interest in as collateral under the three loans with operators that are unconsolidated VIEs. The fair value of the accounts receivable available to Omega was $ 8.7 million and $ 5.9 million as of June 30, 2023 and December 31, 2022, respectively. 22 Table of Contents In determining our maximum exposure to loss from the unconsolidated VIEs, we considered the underlying carrying value of the real estate subject to leases with the operator and other collateral, if any, supporting our other investments, which may include accounts receivable, security deposits, letters of credit or personal guarantees, if any, as well as other liabilities recognized with respect to these operators. The table below reflects our total revenues from the operators that are considered unconsolidated VIEs for the three and six months ended June 30, 2023 and 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ (in thousands) ​ (in thousands) Revenue ​ ​ ​ ​ Rental income $ 25,962 ​ $ 21,239 ​ $ 35,800 ​ $ 42,102 Interest income 979 ​ 4,335 ​ 3,085 ​ 8,101 Total $ 26,941 ​ $ 25,574 ​ $ 38,885 ​ $ 50,203 ​ Consolidated VIEs We own 52.4 % of the outstanding equity of a joint venture, which owns two ALFs, that is a VIE. We have consolidated this VIE as a result of our conclusion that we are the primary beneficiary of this VIE based on a combination of our ability to direct the activities that most significantly impact the joint venture’s economic performance and our rights to receive residual returns or the obligation to absorb losses arising from the joint venture. As of June 30, 2023 and December 31, 2022, this joint venture has $ 26.7 million and $ 25.8 million, respectively, of total assets and $ 20.3 million and $ 19.8 million, respectively, of total liabilities, which are included in our Consolidated Balance Sheets. During the fourth quarter of 2022, we acquired seven facilities using a reverse like-kind exchange structure pursuant to Section 1031 of the Code (a “reverse 1031 exchange”). We completed the reverse 1031 exchange for three of the acquired facilities in the fourth quarter of 2022. During the second quarter of 2023, the remaining four facilities were released from the possession of the Exchange Accommodation Titleholders (“EATs”), as we did not identify any qualifying exchange transactions. The EATs were classified as VIEs as they did not have sufficient equity investment at risk to permit the entity to finance its activities. The Company consolidated the EATs because it had the ability to control the activities that most significantly impacted the economic performance of the EATs and was, therefore, the primary beneficiary of the EATs. The properties held by the EATs were reflected as real estate with a carrying value of $ 55.2 million as of December 31, 2022. The EATs also held cash of $ 23.9 million as of December 31, 2022 . 23 Table of Contents NOTE 9 – INVESTMENTS IN JOINT VENTURES Unconsolidated Joint Ventures The following is a summary of our investments in unconsolidated joint ventures (dollars in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying Amount ​ ​ Ownership ​ Initial Investment ​ ​ ​ ​ Facility ​ Facilities at ​ June 30, ​ December 31, Entity ​ % ​ Date ​ Investment (1) ​ Type ​ June 30, 2023 ​ 2023 2022 Second Spring Healthcare Investments ​ 15 % ​ 11/1/2016 ​ $ 50,032 ​ SNF ​ — ​ $ 10,440 $ 10,975 Lakeway Realty, L.L.C. ​ 51 % ​ 5/17/2019 ​ ​ 73,834 ​ Specialty facility ​ 1 ​ ​ 69,551 ​ ​ 70,151 Cindat Joint Venture ​ 49 % ​ 12/18/2019 ​ ​ 105,688 ​ ALF ​ 63 ​ ​ 103,024 ​ ​ 97,382 OMG Senior Housing, LLC ​ 50 % ​ 12/6/2019 ​ ​ — ​ Specialty facility ​ 1 ​ — ​ — OH CHS SNP, Inc. ​ 9 % ​ 12/20/2019 ​ ​ 1,013 ​ N/A ​ N/A ​ ​ 502 ​ ​ 412 RCA NH Holdings RE Co., LLC (2)(3) ​ 20 % ​ 4/14/2023 ​ ​ 3,400 ​ SNF ​ 5 ​ ​ 3,400 ​ ​ — WV Pharm Holdings, LLC (2)(3) ​ 20 % ​ 4/14/2023 ​ ​ 3,000 ​ N/A ​ N/A ​ ​ 3,000 ​ ​ — OMG-Form Senior Holdings, LLC (3)(4) ​ 49 % ​ 6/15/2023 ​ ​ 1,794 ​ ALF ​ 1 ​ ​ 1,750 ​ ​ — ​ ​ ​ ​ ​ ​ $ 238,761 ​ ​ ​ ​ ​ $ 191,667 ​ $ 178,920 (1) Our investment includes our transaction costs, if any. (2) These joint ventures were entered into in connection with an existing operator’s acquisition of SNFs in West Virginia during the second quarter of 2023, as discussed in Note 5 and Note 6. The acquiring operator in the transaction is the majority owner of these joint ventures. As of June 30, 2023, we have an aggregate of $ 8.5 million of loans outstanding with these joint ventures. (3) These joint ventures are unconsolidated VIEs and therefore are included in the tables in Note 8 – Variable Interest Entities. (4) During the second quarter of 2023, we funded $ 7.7 million under a mortgage loan with this joint venture. The following table reflects our income (loss) from unconsolidated joint ventures for the three and six months ended June 30, 2023 and 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, Entity ​ 2023 2022 ​ 2023 2022 ​ ​ (in thousands) Second Spring Healthcare Investments ​ $ 292 ​ $ 297 ​ $ 581 ​ $ 582 Second Spring II LLC (1) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 2 ) Lakeway Realty, L.L.C. ​ ​ 677 ​ 659 ​ ​ 1,356 ​ 1,320 Cindat Joint Venture ​ 96 ​ 898 ​ 97 ​ 1,633 OMG Senior Housing, LLC ​ 41 ​ ( 96 ) ​ ( 179 ) ​ ( 179 ) OH CHS SNP, Inc. ​ 8 ​ 24 ​ 90 ​ 51 OMG-Form Senior Holdings, LLC ​ ​ ( 45 ) ​ ​ — ​ ​ ( 45 ) ​ ​ — Total ​ $ 1,069 ​ $ 1,782 ​ $ 1,900 ​ $ 3,405 (1) The assets held by this joint venture have been liquidated, and we have no remaining operations related to this joint venture. Asset Management Fees We receive asset management fees from certain joint ventures for services provided. For the three months ended June 30, 2023 and 2022, we recognized approximately $ 0.2 million of asset management fees. For the six months ended June 30, 2023 and 2022, we recognized approximately $ 0.4 million of asset management fees. These fees are included in miscellaneous income in the accompanying Consolidated Statements of Operations. 24 Table of Contents NOTE 10 – GOODWILL AND OTHER INTANGIBLES The following is a summary of our goodwill as of June 30, 2023 and December 31, 2022: ​ ​ ​ ​ ​ (in thousands) Balance as of December 31, 2022 ​ $ 643,151 Foreign currency translation ​ 711 Balance as of June 30, 2023 ​ $ 643,862 ​ The following is a summary of our intangibles as of June 30, 2023 and December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2023 ​ 2022 ​ ​ ​ (in thousands) ​ Assets: ​ ​ ​ ​ Above market leases ​ $ 4,214 ​ $ 5,929 ​ Accumulated amortization ​ ( 3,503 ) ( 4,484 ) ​ Net above market leases ​ $ 711 ​ $ 1,445 ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ Below market leases ​ $ 55,183 ​ $ 66,433 ​ Accumulated amortization ​ ( 40,187 ) ( 44,595 ) ​ Net below market leases ​ $ 14,996 ​ $ 21,838 ​ ​ Above market leases, net of accumulated amortization, are included in other assets on our Consolidated Balance Sheets. Below market leases, net of accumulated amortization, are included in accrued expenses and other liabilities on our Consolidated Balance Sheets. The net amortization related to the above and below market leases is included in our Consolidated Statements of Operations as an adjustment to rental income. For the three months ended June 30, 2023 and 2022, our net amortization related to intangibles was $ 0.7 million and $ 1.0 million, respectively. For the six months ended June 30, 2023 and 2022, our net amortization related to intangibles was $ 6.8 million and $ 2.6 million, respectively. The estimated net amortization related to these intangibles for the remainder of 2023 and the next four years is as follows: remainder of 2023 – $ 1.2 million; 2024 – $ 2.3 million; 2025 – $ 2.3 million; 2026 – $ 2.1 million and 2027 – $ 1.8 million. As of June 30, 2023, the weighted average remaining amortization period of above market lease assets is approximately fourteen years and below market lease liabilities is approximately eight years . ​ NOTE 11 – CONCENTRATION OF RISK As of June 30, 2023, our portfolio of real estate investments (including properties associated with mortgages, direct financing leases, assets held for sale and consolidated joint ventures) consisted of 923 healthcare facilities, located in 42 states and the U.K. and operated by 71 third-party operators. Our investment in these facilities, net of impairments and allowances, totaled approximately $ 9.6 billion at June 30, 2023, with approximately 97 % of our real estate investments related to long-term healthcare facilities. Our portfolio is made up of (i) 661 SNFs, 175 ALFs, 19 ILFs, 17 specialty facilities and one medical office building, (ii) fixed rate mortgages on 44 SNFs, three ALFs and two specialty facilities, and (iii) one facility that is held for sale. At June 30, 2023, we also held other real estate loans receivable (excluding mortgages) of $ 466.6 million, non-real estate loans receivable of $ 227.9 million and $ 191.7 million of investments in eight unconsolidated joint ventures. 25 Table of Contents As of June 30, 2023 and December 31, 2022, we had investments with one operator or manager that approximated or exceeded 10% of our total investments: Maplewood. Maplewood generated approximately 6.5 % and 9.0 % of our total revenues (excluding the impact of write-offs) for the three months ended June 30, 2023 and 2022, respectively, and 7.3 % and 9.0 % of our total revenues for the six months ended June 30, 2023 and 2022, respectively. During the three and six months ended June 30, 2023, we also have one operator with total revenues (excluding the impact of write-offs) that exceeded 10% of our total revenues: CommuniCare Health Services, Inc. (“CommuniCare”). CommuniCare generated approximately 11.4 % and 7.4 % of our total revenues (excluding the impact of write-offs) for the three months ended June 30, 2023 and 2022, respectively, and 10.3 % and 7.4 % of our total revenues for the six months ended June 30, 2023 and 2022, respectively. As of June 30, 2023, CommuniCare represented approximately 8.6 % of our total investments. As of June 30, 2023, the three states in which we had our highest concentration of investments were Florida ( 11.4 %), Texas ( 10.2 %) and Indiana ( 6.6 %). NOTE 12 – STOCKHOLDERS’ EQUITY $500 Million Stock Repurchase Program We had no share repurchases during the three and six months ended June 30, 2023. The following is a summary of the shares repurchased for the three and six months ended June 30, 2022 (in millions except average price per share): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average Price ​ ​ ​ Period Ended Shares Repurchased Per Share (1) Repurchase Cost (1) Three Months Ended June 30, 2022 4.2 $ 27.19 $ 114.9 Six Months Ended June 30, 2022 5.2 ​ 27.32 ​ 142.3 (1) Average price per share and repurchase cost includes the cost of commissions. Dividends The following is a summary of our declared cash dividends on common stock: ​ ​ ​ ​ ​ ​ Record ​ Payment ​ Dividend per Date Date Common Share February 6, 2023 ​ February 15, 2023 ​ $ 0.67 May 1, 2023 ​ May 15, 2023 ​ ​ 0.67 July 31, 2023 ​ August 15, 2023 ​ ​ 0.67 ​ Dividend Reinvestment and Common Stock Purchase Plan The following is a summary of the shares issued under the Dividend Reinvestment and Common Stock Purchase Plan for the three and six months ended June 30, 2023 and 2022 (in millions): ​ ​ ​ ​ ​ ​ ​ Period Ended Shares issued ​ Gross Proceeds Three Months Ended June 30, 2022 0.1 ​ $ 2.3 Three Months Ended June 30, 2023 0.1 ​ ​ 2.2 Six Months Ended June 30, 2022 0.2 ​ ​ 4.6 Six Months Ended June 30, 2023 0.2 ​ ​ 4.5 ​ 26 Table of Contents At-The-Market Offering Programs The following is a summary of the shares issued under our $ 1.0 billion At-The-Market Offering Program (“ATM Program”) for the three and six months ended June 30, 2023 and 2022 (in millions except average price per share): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average Net Price ​ ​ ​ ​ ​ ​ ​ Period Ended Shares issued Per Share (1) Gross Proceeds Commissions Net Proceeds Three and Six Months Ended June 30, 2022 — $ — $ — $ — $ — Three and Six Months Ended June 30, 2023 6.5 ​ 30.20 ​ 199.4 ​ 2.2 ​ 197.2 (1) Represents the average price per share after commissions. Accumulated Other Comprehensive Income (Loss) The following is a summary of our accumulated other comprehensive income (loss), net of tax where applicable: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of and for the As of and for the ​ Three Months Ended ​ Six Months Ended ​ June 30, ​ June 30, ​ 2023 2022 2023 2022 ​ (in thousands) Foreign Currency Translation: ​ ​ ​ ​ ​ Beginning balance $ ( 69,170 ) ​ $ ( 38,668 ) ​ $ ( 85,004 ) ​ $ ( 24,012 ) Translation gain (loss) 17,140 ​ ( 39,750 ) ​ 32,890 ​ ( 54,380 ) Realized gain (loss) 82 ​ ( 1,252 ) ​ 166 ​ ( 1,278 ) Ending balance ( 51,948 ) ​ ( 79,670 ) ​ ( 51,948 ) ​ ( 79,670 ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative Instruments: ​ ​ ​ ​ ​ ​ ​ Cash flow hedges: ​ ​ ​ ​ ​ ​ ​ Beginning balance 76,806 ​ 49,985 ​ 86,356 ​ 30,407 Unrealized gain (loss) 6,125 ​ 18,370 ​ ( 4,499 ) ​ 36,982 Realized gain (1) 1,074 ​ ​ 1,074 ​ 2,148 ​ ​ 2,040 Ending balance 84,005 ​ 69,429 ​ 84,005 ​ 69,429 Net investment hedges: ​ ​ ​ ​ ​ ​ ​ Beginning balance 13,593 ​ ( 5,741 ) ​ 18,634 ​ ( 9,588 ) Unrealized (loss) gain ( 4,015 ) ​ 18,661 ​ ( 9,056 ) ​ 22,508 Ending balance 9,578 ​ 12,920 ​ 9,578 ​ 12,920 Total accumulated other comprehensive income before noncontrolling interest 41,635 ​ 2,679 ​ 41,635 ​ 2,679 Add: portion included in noncontrolling interest ( 282 ) ​ 822 ​ ( 282 ) ​ 822 Total accumulated other comprehensive income for Omega $ 41,353 ​ $ 3,501 ​ $ 41,353 ​ $ 3,501 (1) Recorded in interest expense on the Consolidated Statements of Operations. ​ ​ ​ NOTE 13 – TAXES Omega was organized, has operated and intends to continue to operate in a manner that enables Omega to qualify for taxation as a REIT under Sections 856 through 860 of the Code. On a quarterly and annual basis, we perform several analyses to test our compliance within the REIT taxation rules. If we fail to meet the requirements for qualification as a REIT in any tax year, we will be subject to federal income tax on our taxable income at regular corporate rates and may not be able to qualify as a REIT for the four subsequent years, unless we qualify for certain relief provisions that are available in the event we fail to satisfy any of the requirements. 27 Table of Contents We are also subject to federal taxation of 100 % of the net income derived from the sale or other disposition of property, other than foreclosure property, that we held primarily for sale to customers in the ordinary course of a trade or business. We believe that we do not hold assets for sale to customers in the ordinary course of business and that none of the assets currently held for sale or that have been sold would be considered a prohibited transaction within the REIT taxation rules. As a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. In 2022, we distributed dividends in excess of our taxable income. We currently own stock in certain subsidiary REITs. These subsidiaries are required to individually satisfy all of the rules for qualification as a REIT. If we fail to meet the requirements for qualification as a REIT for any of the subsidiary REITs, it may cause Omega to fail the requirements for qualification as a REIT also. We have elected to treat certain of our active subsidiaries as taxable REIT subsidiaries (“TRSs”). Our domestic TRSs are subject to federal, state and local income taxes at the applicable corporate rates. As of June 30, 2023, one of our TRSs that is subject to income taxes at the applicable corporate rates had a net operating loss (“NOL”) carry-forward of approximately $ 10.2 million. Our NOL carry-forward was fully reserved as of June 30, 2023, with a valuation allowance due to uncertainties regarding realization. Under current law, NOL carry-forwards generated up through December 31, 2017, may be carried forward for no more than 20 years, and NOL carry-forwards generated in taxable years ended after December 31, 2017, may be carried forward indefinitely. We do not anticipate that such changes will materially impact the computation of Omega’s taxable income, or the taxable income of any Omega entity, including our TRSs. Our foreign subsidiaries are subject to foreign income taxes and withholding taxes. As of June 30, 2023, one of our U.K. subsidiaries had a NOL carryforward of approximately $ 42.2 million. The NOLs have no expiration date and may be available to offset future taxable income. We believe these foreign NOLs are realizable under a “more likely than not” measurement and have not recorded a valuation allowance against the deferred tax asset. The majority of our U.K. portfolio elected to enter the U.K. REIT regime with an effective date of April 1, 2023. In connection with entering the U.K. REIT regime, we recognized several adjustments to our deferred tax balances in the first quarter of 2023 as summarized below. The following is a summary of deferred tax assets and liabilities (which are recorded in other assets and accrued expenses and other liabilities in our Consolidated Balance Sheets): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2023 2022 ​ ​ (in thousands) U.S. Federal net operating loss carryforward ​ $ 2,138 ​ $ 2,138 Valuation allowance on deferred tax asset ​ ( 2,138 ) ​ ( 2,138 ) Foreign net operating loss carryforward ​ ​ 10,544 ​ ​ 11,268 Foreign deferred tax liability (1) ​ — ​ ( 5,373 ) Net deferred tax asset ​ $ 10,544 ​ $ 5,895 ​ ​ ​ ​ ​ ​ ​ Foreign deferred tax liability (2) ​ $ 1,422 ​ $ — Net deferred tax liability ​ $ 1,422 ​ $ — (1) The deferred tax liability primarily resulted from inherited basis differences resulting from our acquisition of entities in the U.K. Subsequent adjustments to these accounts result from GAAP to tax differences related to depreciation, indexation and revenue recognition. The foreign deferred tax liabilities were eliminated upon the majority of our U.K. portfolio entering the U.K. REIT regime. (2) The deferred tax liability resulted from book to tax differences recorded in the U.S. relating to depreciation and revenue recognition in the U.K. recognized upon the majority of our U.K. portfolio entering the U.K. REIT regime. 28 Table of Contents The following is a summary of our provision for income taxes: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, Six Months Ended June 30, ​ 2023 2022 2023 2022 ​ (in millions) Federal, state and local income tax expense $ 0.3 $ 0.3 $ 0.6 $ 0.6 Foreign income tax expense (benefit) (1) ​ 1.3 ​ 0.8 ​ ( 0.3 ) ​ 1.7 Total income tax expense (2) $ 1.6 ​ $ 1.1 ​ $ 0.3 ​ $ 2.3 (1) The benefit for the six months ended June 30, 2023 primarily relates to adjustments made to our deferred tax assets and liabilities as a result of the majority of our U.K. portfolio electing to enter into the U.K. REIT regime effective April 1, 2023. (2) The above amounts do not include gross income receipts or franchise taxes payable to certain states and municipalities. NOTE 14 – STOCK-BASED COMPENSATION The following is a summary of our stock-based compensation expense for the three and six months ended June 30, 2023 and 2022, respectively: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Six Months Ended ​ ​ June 30, June 30, ​ 2023 2022 2023 2022 ​ (in thousands) ​ Stock-based compensation expense $ 8,806 $ 6,846 $ 17,550 $ 13,706 ​ Stock-based compensation expense is included within general and administrative expenses on our Consolidated Statements of Operations. We granted 254,777 time-based profits interest units (“PIUs”) during the first quarter of 2023 to certain officers and employees, and those units vest on December 31, 2025 ( three years after the grant date), subject to continued employment and vesting in certain other events. We granted 2,049,878 performance-based PIUs during the first quarter of 2023 to certain officers and employees, which are earned based on the level of performance over the performance period (normally three years ) and vest quarterly in the four th year, subject to continued employment and vesting in certain other events. We also granted 59,684 performance-based restricted stock units (“RSUs”) during the first quarter of 2023 to certain employees, which are earned based on the level of performance over the performance period (normally three years ) and vest on December 31, 2025, subject to continued employment. We granted 26,254 time-based PIUs and 25,224 time-based RSUs to directors during the second quarter of 2023, and those units vest on Omega’s 2024 annual meeting date, subject to the director’s continued service and vesting in certain other events. Time-based and performance-based grants made to named executive officers and key employees that meet certain conditions under the Company’s retirement policy (length of service, age, etc.) vest on an accelerated basis pursuant to the 2018 Stock Incentive Plan. 29 Table of Contents NOTE 15 – BORROWING ACTIVITIES AND ARRANGEMENTS The following is a summary of our borrowings: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Annual ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest Rate ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ June 30, ​ December 31, ​ Maturity 2023 ​ 2023 2022 ​ ​ ​ ​ (in thousands) Secured borrowings: ​ ​ ​ HUD mortgages (1)(2) ​ 2046 - 2052 ​ 3.01 % (3) ​ $ 340,869 ​ $ 344,708 2023 term loan (4) 2023 N/A ​ ​ ​ — ​ ​ 2,161 2024 term loan (5) 2024 10.67 % ​ ​ 19,906 ​ ​ 19,727 Total secured borrowings ​ ​ ​ ​ ​ ​ ​ 360,775 ​ ​ 366,596 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unsecured borrowings: ​ ​ ​ Revolving credit facility (6)(7) 2025 6.42 % ​ 20,342 ​ 19,246 ​ ​ ​ ​ ​ ​ ​ ​ 20,342 ​ ​ 19,246 Senior notes and other unsecured borrowings: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 notes (6)(8) 2023 4.375 % ​ 350,000 ​ 350,000 2024 notes (6) 2024 4.950 % ​ 400,000 ​ 400,000 2025 notes (6) 2025 4.500 % ​ 400,000 ​ 400,000 2026 notes (6) 2026 5.250 % ​ 600,000 ​ 600,000 2027 notes (6) 2027 4.500 % ​ 700,000 ​ 700,000 2028 notes (6) 2028 4.750 % ​ 550,000 ​ 550,000 2029 notes (6) 2029 3.625 % ​ 500,000 ​ 500,000 2031 notes (6) ​ 2031 ​ 3.375 % ​ ​ 700,000 ​ ​ 700,000 2033 notes (6) ​ 2033 ​ 3.250 % ​ ​ 700,000 ​ ​ 700,000 OP term loan (9)(10) 2025 5.52 % ​ 50,000 ​ 50,000 Deferred financing costs – net ​ ​ ​ ( 19,923 ) ​ ( 22,276 ) Discount – net ​ ​ ( 24,316 ) ​ ( 26,732 ) Total senior notes and other unsecured borrowings – net ​ ​ 4,905,761 ​ 4,900,992 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total unsecured borrowings – net ​ ​ 4,926,103 ​ 4,920,238 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total secured and unsecured borrowings – net (11)(12) ​ ​ $ 5,286,878 ​ $ 5,286,834 (1) Reflects the weighted average annual contractual interest rate on the mortgages at June 30, 2023. The mortgages are secured by real estate assets with a net carrying value of $ 470.8 million as of June 30, 2023. (2) Wholly owned subsidiaries of Omega OP are the obligor on these borrowings. (3) Excludes fees of approximately 0.65 % for mortgage insurance premiums. (4) Borrowing was the debt of a consolidated joint venture. (5) Borrowing is the debt of the consolidated joint venture discussed in Note 8 – Variable Interest Entities which was formed in the first quarter of 2022. The borrowing is secured by two ALFs, which are owned by the joint venture. (6) Guaranteed by Omega OP. (7) During the second quarter of 2023, the Company transitioned its benchmark interest rate for its $ 1.45 billion senior unsecured multicurrency revolving credit facility from LIBOR to SOFR . As of June 30, 2023, borrowings under Omega’s $ 1.45 billion senior unsecured multicurrency revolving credit facility consisted of £ 16.0 million British Pounds Sterling (“GBP”). The applicable interest rate on the US Dollar tranche and on the GBP borrowings under the alternative currency tranche of the credit facility were 6.42 % and 6.25 % as of June 30, 2023, respectively. (8) On August 1, 2023, the Company repaid the $ 350 million of 4.375 % senior notes that matured on August 1, 2023 using available cash. (9) Omega OP is the obligor on this borrowing. (10) During the second quarter of 2023, the Company transitioned its benchmark interest rate for its $ 50.0 million senior unsecured term loan facility from LIBOR to SOFR . The weighted average interest rate of the $ 50 million OP term loan has been adjusted to reflect the impact of the interest rate swaps that effectively fix the SOFR based portion of the interest rate at 3.957 % . (11) All borrowings are direct borrowings of Parent unless otherwise noted. (12) Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of June 30, 2023 and December 31, 2022, we were in compliance with all applicable covenants for our borrowings . 30 Table of Contents NOTE 16 – DERIVATIVES AND HEDGING We are exposed to, among other risks, the impact of changes in foreign currency exchange rates as a result of our investments in the U.K. and interest rate risk related to our capital structure. As a matter of policy, we do not use derivatives for trading or speculative purposes. Our risk management program is designed to manage the exposure and volatility arising from these risks, and utilizes foreign currency forward contracts, interest rate swaps and debt issued in foreign currencies to offset a portion of these risks. As of June 30, 2023, we have one interest rate swap with $ 50.0 million in notional value that was entered into during the second quarter of 2023 (discussed further below). The swap is designated as a cash flow hedge. Additionally, we have six foreign currency forward contracts with £ 250.0 million in notional valued issued at a weighted average GBP-USD forward rate of 1.3641 that are designated as net investment hedges. In June 2023, we entered into an interest rate swap with a notional amount of $ 50.0 million. The swap is effective June 30, 2023 and terminates on April 30, 2027 . This interest rate swap is designated as a hedge against our exposure to changes in interest payment cash flow fluctuations in the variable interest rates on the OP Term Loan. The interest rate swap contract effectively converts our $ 50.0 million OP Term Loan to an aggregate fixed rate of approximately 5.52 % through its maturity. The effective fixed rate achieved by the combination of the 2021 Omega OP Credit Agreement and the interest rate swaps could fluctuate up by 40 basis points or down by 60 basis points based on future changes to our credit ratings. In March 2020, we entered into five forward starting swaps with $ 400 million in notional value, indexed to 3-month LIBOR, that were issued at a weighted average fixed rate of 0.8675 % and were subsequently designated as cash flow hedges. In conjunction with the October 2020 issuance of $ 700 million of 3.375 % Senior Notes due 2031 and the March 2021 issuance of $ 700 million of 3.25 % Senior Notes due 2033, we applied hedge accounting for these five forward starting swaps and began amortization. Simultaneously with these issuances, we re-designated these swaps in new cash flow hedging relationships of interest rate risk associated with interest payments for a future forecasted issuance of long-term debt. As a result of these transactions, the aggregate unrealized gain of $ 41.2 million ( $ 9.5 million gain related to the October 2020 issuance and $ 31.7 million gain related to the March 2021 issuance) included within accumulated other comprehensive income at the time of the bond issuances is being ratably reclassified as a reduction to interest expense, net over 10 years. On May 30, 2023, the five forward starting swaps were terminated, and Omega received a net cash settlement of $ 92.6 million from the swap counterparties. The incremental $ 51.4 million of gains related to the forward swaps, recorded in accumulated other comprehensive income, were frozen at the time of termination and will be recognized ratably over 10 years in earnings when the next qualifying debt issuance occurs. Consistent with our accounting policy and historical practice, the $ 92.6 million net cash settlement from the forward swap termination is reflected within net cash used in financing activities in the Consolidated Statements of Cash Flows. The location and fair value of derivative instruments designated as hedges, at the respective balance sheet dates, were as follows: ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2023 2022 Cash flow hedges: (in thousands) Other assets $ 211 ​ $ 92,990 ​ ​ ​ ​ ​ ​ Net investment hedges: ​ ​ ​ ​ ​ Other assets $ 25,921 ​ $ 34,977 ​ The fair value of the interest rate swap and foreign currency forwards is derived from observable market data such as yield curves and foreign exchange rates and represents a Level 2 measurement on the fair value hierarchy. 31 Table of Contents NOTE 17 – FINANCIAL INSTRUMENTS The net carrying amount of cash and cash equivalents, restricted cash, contractual receivables, other assets and accrued expenses and other liabilities reported in the Consolidated Balance Sheets approximates fair value because of the short maturity of these instruments (Level 1). At June 30, 2023 and December 31, 2022, the net carrying amounts and fair values of our other financial instruments were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ December 31, 2022 ​ Carrying Fair Carrying Fair ​ Amount Value Amount Value ​ ​ (in thousands) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Investments in direct financing leases – net ​ $ 8,995 ​ $ 8,995 $ 8,503 ​ $ 8,503 Real estate loans receivable – net ​ 1,096,806 ​ ​ 1,115,784 ​ ​ 1,042,731 ​ ​ 1,080,890 Non-real estate loans receivable – net ​ 227,916 ​ ​ 229,294 ​ ​ 225,281 ​ ​ 228,498 Total ​ $ 1,333,717 ​ $ 1,354,073 ​ $ 1,276,515 ​ $ 1,317,891 Liabilities: ​ ​ ​ ​ Revolving credit facility ​ $ 20,342 ​ $ 20,342 $ 19,246 ​ $ 19,246 2023 term loan ​ ​ — ​ ​ — ​ ​ 2,161 ​ ​ 2,275 2024 term loan ​ 19,906 ​ ​ 19,750 ​ ​ 19,727 ​ ​ 19,750 OP term loan ​ 49,813 ​ ​ 50,000 ​ ​ 49,762 ​ ​ 50,000 4.375 % notes due 2023 – net ​ 349,953 ​ ​ 349,395 ​ ​ 349,669 ​ ​ 347,998 4.95 % notes due 2024 – net ​ 399,242 ​ ​ 394,324 ​ ​ 398,736 ​ ​ 394,256 4.50 % notes due 2025 – net ​ 398,827 ​ ​ 384,000 ​ ​ 398,446 ​ ​ 388,920 5.25 % notes due 2026 – net ​ 598,200 ​ ​ 576,426 ​ ​ 597,848 ​ ​ 589,104 4.50 % notes due 2027 – net ​ 694,570 ​ ​ 645,813 ​ ​ 693,837 ​ ​ 657,468 4.75 % notes due 2028 – net ​ 545,420 ​ ​ 499,856 ​ ​ 544,916 ​ ​ 507,425 3.625 % notes due 2029 – net ​ ​ 492,494 ​ ​ 408,490 ​ ​ 491,890 ​ ​ 411,090 3.375 % notes due 2031 – net ​ ​ 686,277 ​ ​ 547,806 ​ ​ 685,382 ​ ​ 540,386 3.25 % notes due 2033 – net ​ ​ 690,965 ​ ​ 509,859 ​ ​ 690,506 ​ ​ 507,976 HUD mortgages – net ​ ​ 340,869 ​ ​ 305,896 ​ ​ 344,708 ​ ​ 266,161 Total ​ $ 5,286,878 ​ $ 4,711,957 ​ $ 5,286,834 ​ $ 4,702,055 ​ Fair value estimates are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument (see Note 2 – Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2022). The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts. The following methods and assumptions were used in estimating fair value disclosures for financial instruments. ● Real estate loans receivable: The fair value of the real estate loans receivables are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). ● Non-real estate loans receivable: Non-real estate loans receivable are primarily comprised of notes receivable. The fair values of notes receivable are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). 32 Table of Contents ● Revolving credit facility, OP term loan, 2023 term loan and 2024 term loan: The carrying amount of these approximate fair value because the borrowings are interest rate adjusted. Differences between carrying value and the fair value in the table above are due to the inclusion of deferred financing costs in the carrying value. ● Senior notes: The fair value of the senior unsecured notes payable was estimated based on (Level 1) publicly available trading prices. ● HUD mortgages: The fair value of our borrowings under HUD debt agreements are estimated using an expected present value technique based on quotes obtained by HUD debt brokers (Level 2). NOTE 18 – COMMITMENTS AND CONTINGENCIES Litigation Shareholder Litigation The Company and certain of its officers, C. Taylor Pickett, Robert O. Stephenson, and Daniel J. Booth , were named as defendants in a purported securities class action lawsuit in the U.S. District Court for the Southern District of New York (the “Securities Class Action”). Brought by lead plaintiff Royce Setzer and additional plaintiff Earl Holtzman, the Securities Class Action purported to assert claims for violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, as well as Section 20(a) of the Exchange Act, and sought monetary damages, interest, fees and expenses of attorneys and experts, and other relief. The Securities Class Action alleged that the defendants violated the Exchange Act by making materially false and/or misleading statements, and by failing to disclose material adverse facts about the Company’s business, operations, and prospects, including the financial and operating results of one of the Company’s operators, the ability of such operator to make timely rent payments, and the impairment of certain of the Company’s leases and the uncollectibility of certain receivables. The plaintiffs and defendants executed a stipulation of settlement dated December 9, 2022 (“Settlement”), which provided for dismissal and release of all claims against the defendants by a class of persons and/or entities who purchased or otherwise acquired Company securities from February 8, 2017 through October 31, 2017 without any admission of wrongdoing or liability on the part of the Company or the individual defendants. On April 25, 2023, following notice to class members and a hearing, the Court entered judgment approving the Settlement, which became effective May 25, 2023, upon the expiration of the period for appealing the Court’s judgment. Upon the effective date of the Settlement, the Settlement payment of $ 30.75 million was permitted to be transmitted from an escrow account funded by the Company’s directors and officers insurers to a settlement fund to be distributed to class members by a third party administrator. In the second quarter of 2023, after the Company fulfilled all of its obligations pursuant to the Court-approved Settlement, the Company reversed the previously recorded $ 31 million legal reserve, which was included within accrued expenses and other liabilities on the Consolidated Balance Sheets, and the related $ 31 million receivable related to the insurance reimbursement, which was included within other assets on the Consolidated Balance Sheets. Certain derivative actions have also been brought against the officers named in the Securities Class Action, and certain current and former directors of the Company, alleging claims relating to the matters at issue in the Securities Class Action. In 2018, Stourbridge Investments LLC, a purported stockholder of the Company, filed a derivative action purportedly on behalf of the Company in the U.S. District Court for the Southern District of New York, alleging violations of Section 14(a) of the Exchange Act and state-law claims including breach of fiduciary duty. The complaint alleges, among other things, that the named defendants are responsible for the Company’s failure to disclose the financial condition of Orianna Health Systems, the alleged non-disclosures that were also the subject of the Securities Class Action described above. The plaintiff did not make a demand on the Company to bring the action prior to filing it, but rather alleges that demand would have been futile. 33 Table of Contents In 2019, purported stockholder Phillip Swan by his counsel, and stockholders Tom Bradley and Sarah Smith by their counsel, filed derivative actions in the Baltimore City Circuit Court of Maryland, purportedly on behalf of the Company, asserting claims for breach of fiduciary duty, waste of corporate assets and unjust enrichment against the named defendants. Those actions were consolidated. Prior to filing suit, each of these stockholders had made demands on the Board of Directors in 2018 that the Company bring such lawsuits. After an investigation and due consideration, and in the exercise of its business judgment, the Board of Directors determined that it is not in the best interests of the Company to commence litigation against any current or former officers or directors based on the matters raised in the demands. In addition, in late 2020, Robert Wojcik, a purported shareholder of the Company, filed a derivative action in the U.S. District Court for the District of Maryland, purportedly on behalf of the Company, asserting violations of Section 14(a) of the Exchange Act, Sections 10(b) and 21D of the Exchange Act, as well as claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. Wojcik also did not make a demand on the Company prior to filing suit. Other Gulf Coast Subordinated Debt In August 2021, we filed suit in the Circuit Court for Baltimore County (the “Court”) against the holders of certain Subordinated Debt (the “Debt Holders”) associated with our Gulf Coast master lease agreement, following an assertion by the Debt Holders that our prior exercise of offset rights in connection with Gulf Coast’s non-payment of rent had resulted in defaults under the terms of the Subordinated Debt. The suit seeks a declaratory judgment to, among other items, declare that the aggregate amount of unpaid rent due from Gulf Coast under the master lease agreement exceeds all amounts which otherwise would be due and owing by an indirect subsidiary of Omega (“Omega Obligor”) under the Subordinated Debt, and that all principal and interest due and owing under the Subordinated Debt may be (and was) offset in full as of December 31, 2021. In October 2021, the Debt Holders filed a motion to dismiss for lack of personal jurisdiction. On November 3, 2022, the Court granted the Debt Holders’ motion to dismiss for lack of personal jurisdiction, and Omega filed a timely appeal of the ruling. While Omega believes Omega Obligor is entitled to the enforcement of the offset rights sought in the action, Omega cannot predict the outcome of the declaratory judgment action, irrespective of whether (a) it is ultimately litigated in the Court if Omega Obligor prevails in its appeal or (b) if the order granting the motion to dismiss for lack of personal jurisdiction is affirmed and the issues are litigated in the Delaware Court (as defined below). On or about January 19, 2023, the Debt Holders served a lawsuit against the Omega Obligor in the Superior Court of the State of Delaware (the “Delaware Court”), asserting claims for (i) breach of the instruments evidencing the Subordinated Debt, (ii) declaratory judgment, and (iii) unjust enrichment, all claims that are factually based on the claims that are the subject of Omega Obligor’s suit in the Court and that are now on appeal. On February 8, 2023, Omega Obligor filed a motion to dismiss or, in the alternative, to stay this action pending the outcome of the above-referenced lawsuit in Maryland. On July 10, 2023, the Delaware state court case stayed the proceeding pending a hearing in September 2023. Omega believes that the claims are baseless and is evaluating procedural and substantive legal options in connection with this recently filed suit to the extent the stay is lifted. Other In addition to the matters above, we are subject to various other legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or claim has an element of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all of them combined, will not have a material adverse effect on our consolidated financial position or results of operations. 34 Table of Contents Indemnification Agreements In connection with certain facility transitions, we have agreed to indemnify certain operators in certain events. As of June 30, 2023, our maximum funding commitment under these indemnification agreements was approximately $ 9.1 million. Claims under these indemnification agreements generally may be made within 18 months to 72 months of the transition date. These indemnification agreements were provided to certain operators in connection with facility transitions and generally would be applicable in the event that the prior operators do not perform under their transition agreements. Commitments We have committed to fund the construction of new leased and mortgaged facilities, capital improvements and other commitments. We expect the funding of these commitments to be completed over the next several years. Our remaining commitments at June 30, 2023, are outlined in the table below (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lessor construction and capital commitments under lease agreements ​ $ 230,162 ​ ​ Non-real estate loan commitments ​ 66,709 ​ ​ Other real estate loan commitments ​ 48,803 ​ ​ Construction and capital expenditure mortgage loan commitments ​ 8,036 ​ ​ Total remaining commitments (1) ​ $ 353,710 ​ ​ (1) Includes finance costs . NOTE 19 – EARNINGS PER SHARE The following tables set forth the computation of basic and diluted earnings per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Six Months Ended ​ June 30, June 30, ​ 2023 2022 2023 2022 ​ ​ (in thousands, except per share amounts) Numerator: ​ ​ ​ ​ ​ Net income available to common stockholders – basic ​ $ 59,856 ​ $ 89,467 ​ $ 95,798 ​ $ 279,074 Add: net income attributable to OP Units ​ 1,767 ​ 2,448 ​ ​ 2,815 ​ 7,997 Net income available to common stockholders – diluted ​ $ 61,623 ​ $ 91,915 ​ $ 98,613 ​ $ 287,071 Denominator: ​ ​ ​ ​ Denominator for basic earnings per share ​ 236,233 ​ 235,847 ​ 235,594 ​ 237,687 Effect of dilutive securities: ​ ​ ​ ​ ​ ​ ​ ​ Common stock equivalents ​ 2,893 ​ 707 ​ 2,139 ​ 835 Noncontrolling interest – Omega OP Units ​ 6,974 ​ 6,772 ​ 6,912 ​ 6,919 Denominator for diluted earnings per share ​ 246,100 ​ 243,326 ​ 244,645 ​ 245,441 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings per share – basic: ​ ​ ​ ​ Net income available to common stockholders ​ $ 0.25 ​ $ 0.38 ​ $ 0.41 ​ $ 1.17 Earnings per share – diluted: ​ ​ ​ ​ ​ ​ ​ ​ Net income available to common stockholders ​ $ 0.25 ​ $ 0.38 ​ $ 0.40 ​ $ 1.17 ​ ​ ​ 35 Table of Contents NOTE 20 – SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS The following are supplemental disclosures to the Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ ​ 2023 2022 ​ (in thousands) ​ Reconciliation of cash and cash equivalents and restricted cash: ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 350,691 ​ $ 164,949 ​ Restricted cash ​ 5,820 ​ 3,515 ​ Cash, cash equivalents and restricted cash at end of period ​ $ 356,511 ​ $ 168,464 ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental information: ​ ​ ​ ​ ​ Interest paid during the period, net of amounts capitalized ​ $ 111,540 ​ $ 110,266 ​ Taxes paid during the period ​ $ 1,936 ​ $ 3,125 ​ ​ ​ ​ ​ ​ ​ ​ ​ Non-cash investing activities: ​ ​ ​ Non-cash acquisition of real estate ​ $ — ​ $ ( 9,818 ) ​ ​ ​ ​ ​ ​ ​ ​ ​ Non-cash financing activities: ​ ​ ​ Non-cash contribution from noncontrolling member of consolidated joint venture ​ $ — ​ $ 2,903 ​ Change in fair value of cash flow hedges ​ $ ( 9,258 ) ​ $ 63,668 ​ Remeasurement of debt denominated in a foreign currency ​ $ 1,096 ​ $ ( 6,128 ) ​ ​ NOTE 21 – SUBSEQUENT EVENTS On August 1, 2023, the Company repaid its $ 350 million of 4.375 % senior notes that matured on August 1, 2023 using available cash. The Company had $ 350.7 million in cash and cash equivalents recorded on our Consolidated Balance Sheets as of June 30, 2023. ​ ​ ​ ​ 36 Table of Contents